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ABSTRACT
The United States is currently facing a “concussion epidemic.” 
Concussions, also known as mild traumatic brain injuries, have 
increased in numerous settings, including transportation accidents, 
military combat, workplace injuries, domestic abuse, falls, and
sports. The epidemic imposes huge costs on society. At the same 
time, our understanding of the injury remains limited. Currently, no 
proven way exists to physiologically detect concussion risk or 
damage. Determining whether a concussion has occurred and been 
resolved remains largely a clinical diagnosis, relying mostly on self-
reported symptoms. Our knowledge of long-term implications of 
repetitive concussions is also limited. Science is racing to develop 
objective measures, or biomarkers, of concussive injury that will tell 
us who is more likely than not to be susceptible to harm and the 
extent of harm they may have already suffered. The availability of 
biomarkers will lead to a deeper understanding of changes to the 
brain that occur in a concussion and enable us to trace back earlier 
into what we think of as a diseased state.  
These scientific developments will have enormous implications 
for questions of risk and loss distribution in society. In particular, 
they portend a major reexamination of fundamental tort issues of 
duty, breach, causation, and fault allocation. Applying the 
developing research to the legal landscape will shed light on duties, 
as well as causal issues, and may help substantiate latent injury 
claims. This Article examines those questions in the context of youth 
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sports. The development of biomarkers will modify responsibilities 
for mitigating risks, screening, and monitoring players. It will affect 
the ability of the player to assume risks and will also implicate 
certain privacy interests. In general, the development of these 
biomarkers will shift responsibilities in the diagnosis and 
management of concussions, as well as long-term injuries, to those 
most directly involved in the player’s participation. 
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INTRODUCTION
Our nation is facing an epidemic of concussive brain injuries, 
usually referred to in the medical world as mild traumatic brain 
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injuries (mTBI).1 This epidemic of mTBI imposes enormous human 
and economic costs on society. A major impediment to preventing, 
diagnosing, and treating such brain injuries is the lack of objective 
and feasible medical tests to detect such injuries. Over the past few 
years, scientific research has begun to develop accurate, objective 
diagnostic measures of the injury—especially concussive injury. The 
advances from this explosion of research will upend assumptions that 
underlie current medical and policy approaches to mTBI, and will 
create a myriad of new legal applications, opportunities, and 
challenges. In particular, the potential development of objective 
diagnostic tests of concussive injury through biomarkers, as well as 
potential tests of susceptibility, requires us to reexamine fundamental 
issues of risk, duty, causation, and allocation of fault. 
A few cases illustrate the nature of the TBI problem. Curtis 
Parker was an amateur wrestler who went to a local gym to improve 
his wrestling.2 His trainer instructed him to leave the ring due to his 
complaints of a headache; Curtis returned six days later and, after 
falling to the mat, went into a seizure.3 He died nine days later.4
Curtis’s parents brought a wrongful death action against the club and 
the trainer, alleging that they “failed to exercise reasonable care in 
not requiring Curtis to obtain medical clearance before allowing him 
to resume his [] lessons.”5 The plaintiffs’ expert testified that Curtis’s
subdural hemorrhage resulted from second-impact syndrome, in 
which individuals who suffer a second concussion before fully 
recovering from a prior concussion are more susceptible to serious 
brain injury.6 On cross-examination, the expert acknowledged that 
                                                     
1. Kimberly G. Harmon et al., American Medical Society for Sports 
Medicine Position Statement: Concussion in Sport, 47 BRIT. J. SPORTS MED. 15, 16-
17 (2013). A note on terminology: most lay people, policymakers, athletes, and 
coaches use the term “concussion” to refer to a constellation of neurological 
symptoms, such as dizziness, clouded thinking, and even unconsciousness, that can 
result from a head trauma. However, the term concussion is not a medically precise 
or defined term. Rather, specialists refer to mild traumatic brain injury, with the 
word “mild” distinguishing concussive injuries from more severe brain injuries 
resulting from major traumas, such as a bullet, explosion, or car accident that 
permanently disfigures the brain. While all concussions are considered mTBIs, not 
all mTBIs are concussions. More background on this terminology and definitions is 
provided in infra Section I.A. 
2. Parker v. S. Broadway Athletic Club, 230 S.W.3d 642, 643 (Mo. Ct. 
App. 2007).  
3. Id. at 644.  
4. Id.  
5. Id. 
6. Id. at 644-45; see infra note 80 and accompanying text. 
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many kinds of headaches occur, not all of which stem from a 
concussion, and that other symptoms of concussions exist, none of 
which Curtis complained of.7 The trial court held that the plaintiffs 
did not establish that the club knew or should have known that Curtis 
had sustained a concussion at the earlier lesson and entered judgment 
in favor of defendants, which was affirmed on appeal.8
Chris Benoit, nicknamed “The Canadian Crippler,” was a 
champion professional wrestler with World Wrestling 
Entertainment.9 In 2007, after having twenty-two years of experience 
in the ring, he murdered his wife and seven-year-old son and then 
hanged himself.10 Although there was much speculation about the 
cause of this shocking event—ranging from steroids usage to a 
failing marriage—Dr. Julian Bailes, Jr., then the Chair of 
Neurosurgery at West Virginia University, and his colleagues 
suspected brain damage from repeated concussive injury and 
received permission to examine slices of Benoit’s brain.11 They 
discovered that Benoit’s brain was severely damaged and, like an 
Alzheimer’s patient, his brain was riddled with aggregates of a 
neural protein called tau.12 These tangled deposits were consistent 
with severe chronic traumatic encephalopathy (CTE), a progressive 
degenerative neurological disease found in individuals who have 
been subjected to multiple concussions and other forms of head 
injuries.13 Currently, this form of brain damage can be confirmed 
                                                     
7. Parker, 230 S.W.3d at 645.  
8. Id.  
9. Brenda Goodman, Wrestler Killed Wife and Son, Then Himself, N.Y.
TIMES, June 27, 2007, at A15. 
10. Stephanie Cajigal, NEUROLOGY TODAY, Sept. 18, 2007, at 1, 16, 
http://journals.lww.com/neurotodayonline/Fulltext/2007/09180/Brain_Damage_May_ 
Have_Contributed_to_Former.1.aspx; RICHARD BERGER, A FOOL FOR OLD SCHOOL 
. . . WRESTLING, THAT IS 79 (2009). 
11. Id.  
12. Benoit’s Brain Showed Severe Damage from Multiple Concussions, 
Doctor and Dad Say, GOOD MORNING AM., http://abcnews.go.com/GMA/ 
story?id=3560015 (last visited Feb. 13, 2016); see also Bennet I. Omalu et al., 
Chronic Traumatic Encephalopathy, Suicides and Parasuicides in Professional 
American Athletes: The Role of the Forensic Pathologist, 31 AM. J. FORENSIC MED.
PATHOLOGY 130, 130-32 (2010) [hereinafter Omalu et al., Suicides and 
Parasuicides].
13. Wrestler Chris Benoit Brain’s Forensic Exam Consistent with 
Numerous Brain Injuries, SCI. DAILY (Sept. 6, 2007), http://www.sciencedaily.com/ 
releases/2007/09/070905224343.htm [hereinafter Sports Legacy Institute]; Bennet I. 
Omalu et al., Chronic Traumatic Encephalopathy in a Professional American 
Wrestler, 6 J. FORENSIC NURSING. 130, 130-36 (2010) [hereinafter Omalu et al., 
American Wrestler].
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only by autopsy.14 Symptoms of the disease, which include memory 
loss, depression, suicidal thoughts, and aggressive behavior,15 also 
have been noted in ice hockey players, soccer players, boxers, and 
professional football players.16
San Francisco 49ers linebacker Chris Borland, twenty-four and 
fresh off his first season of playing in the NFL, announced his 
retirement from football because of his concerns about the long-term 
effects of repetitive head trauma.17 As he explained, “I just honestly 
want to do what’s best for my health. . . . From what I’ve researched 
and what I’ve experienced, I don’t think it’s worth the risk.”18 He 
was explicit about his apprehension about brain injuries,19 stating, “I
don’t want to have any neurological diseases or die younger than I 
would otherwise.”20
These three examples illustrate the types of challenges 
presented by this enormous public health problem facing our nation 
today, which include the difficulty of accurately diagnosing 
concussions and determining who is qualified to do so, the search for 
other diagnostic measures, and the growing medical and public 
awareness of the long-term effects of concussions. Experts at the 
                                                     
14. Sports Legacy Institute, supra note 13; Omalu et al., American 
Wrestler, supra note 13, at 135. 
15. Helen Ling, John Hardy & Henrik Zetterburg, Neurological 
Consequences of Traumatic Brain Injuries in Sports, 66 MOLECULAR & CELLULAR 
NEUROSCIENCE 114, 119-20 (2015) (reviewing these symptoms and other 
consequences of TBI across a range of contact sports). 
16. Id. at 118-19; see also Jeffrey G. Caron & Gordon A. Bloom, Ethical 
Issues Surrounding Concussions and Player Safety in Professional Ice Hockey,
8 NEUROETHICS 5, 6 (2015) (reviewing data on concussion incidence rates in ice 
hockey); Chadwick Hales et al., Late-Stage CTE Pathology in a Retired Soccer 
Player with Dementia, 83 NEUROLOGY 2307, 2307 (2014); Paul McCrory, Tsharni 
Zazryn & Peter Cameron, The Evidence for Chronic Traumatic Encephalopathy in 
Boxing, 37 SPORTS MED. 467, 467 (2007).  
17. Ashley Fantz & Steve Almasy, Chris Borland, 24, to Retire from NFL, 
Cites Fear of Concussions, CNN (Mar. 17, 2015, 8:37 PM), http://www.cnn.com/ 
2015/03/17/football/chris-borland-retirement-nfl-concussions/index.html. 
18. Id.  
19. Ken Belson, Chris Borland, Fearing for Health, Retires from 49ers. 
At 24., N.Y. TIMES, Mar. 18, 2015, at A1.  
20. Mark Fainaru-Wada & Steve Fainaru, SF’s Borland Quits over Safety 
Issues, ESPN (Mar. 17, 2015), http://espn.go.com/espn/otl/story/_/id/12496480/san-
francisco-49ers-linebacker-chris-borland-retires-head-injury-concerns. He explained 
that “when you read about Mike Webster and Dave Duerson and Ray Easterling, 
you read all these stories, and to be the type of player I want to be in football, I think 
I’d have to take on some risks that, as a person, I don’t want to take on.” Id. He was 
referring to prominent NFL players who were diagnosed with CTE after their 
deaths. Id. “Duerson and Easterling committed suicide.” Id. 
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Centers for Disease Control and Prevention (CDC) estimate that 2.5 
million people sustain a traumatic brain injury (TBI) every year in 
the United States, many in contact sports, such as football, hockey, 
and soccer, but also as a result of military combat, workplace 
injuries, domestic abuse, vehicle crashes, falls, head injuries during 
seizures, and other accidents.21 Resulting brain damage can have 
short-term effects in learning and memory, as well as long-term 
effects.22 The CDC report estimates that the total costs to society as a 
result of these injuries exceed $76 billion per year.23
Society has begun to respond to this TBI epidemic, from policy 
making at the front end to litigation at the back end. At the front end, 
policymakers at the federal, state, and local levels all have 
acknowledged the national health problem. The Department of 
Defense and the Department of Veterans Affairs have expanded their 
funding for research in brain injury.24 States have addressed 
concussion management in high school sports through legislation 
and regulations.25 Local school districts and sports programs have 
changed their rules for participation in those programs.26
On the litigation front, professional and collegiate athletes have 
brought lawsuits against their leagues. More than 5,000 former 
players in the National Football League (NFL) sued the NFL, 
claiming it failed to take reasonable steps to protect them from 
concussive brain injuries, while at the same time concealing the 
                                                     
21. See CTR. FOR DISEASE CONTROL AND PREVENTION, TRAUMATIC BRAIN 
INJURY IN THE UNITED STATES: EPIDEMIOLOGY AND REHABILITATION 2 (2014), http:// 
www.cdc.gov/traumaticbraininjury/pdf/TBI_Report_to_Congress_Epi_and_Rehab-a.pdf 
[hereinafter CDC, Addressing Critical Gaps] (citing MARK FAUL ET AL., TRAUMATIC 
BRAIN INJURY IN THE UNITED STATES: EMERGENCY DEPARTMENT VISITS,
HOSPITALIZATIONS AND DEATHS 2002–2006 (2010), http://www.cdc.gov/ 
traumaticbraininjury/pdf/blue_book.pdf). TBI remains a leading cause of injury and 
death of adults, along with general trauma. See Michael DeCuypere & Paul Klimo 
Jr., Spectrum of Traumatic Brain Injury from Mild to Severe, 92 SURGICAL CLINICS 
N. AM., 939, 940 (2012).  
22. CDC, Addressing Critical Gaps, supra note 21, at 3. 
23. Severe TBI, CDC, http://www.cdc.gov/TraumaticBrainInjury/severe.html 
(last visited Mar. 4, 2016). 
24. Press Release, Dept. of Veterans Affairs, VA and DoD to Fund $100 
Million PTSD and TBI Study (Sept. 19, 2012), http://www.va.gov/opa/pressrel/ 
pressrelease.cfm?id=2386; see Barry Meier & Danielle Ivory, Concussion Inc., N.Y.
TIMES, July 5, 2015, at BU1. 
25. See infra Subsection II.A.1.a. 
26. See, e.g., Trisha Volpe, Focus on Concussions Transforms High School 
Football in Minnesota, MPR NEWS (Sept. 30, 2014), http://www.mprnews.org/story/ 
2014/09/30/high-school-concussions-transform-high-school-football-in-minnesota. 
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long-term risks associated with concussion.27 The settlement of that 
class action lawsuit covers all retired former professional football 
players and provides individual payments of up to $5 million for 
certain neurological disorders and medical monitoring of all 
players.28
The National Collegiate Athletic Association (NCAA),29 the 
National Hockey League,30 soccer’s Federation Internationale de 
Football Association (FIFA),31 and World Wrestling Entertainment32
are all currently embroiled in lawsuits involving athletes’ head 
injuries. These claims are reaching the high school level as well.33
The reverberations of these legal clashes are changing how head 
injuries are handled in football and other sports, across all ages. 
Professional sports organizations,34 high school programs,35 and 
                                                     
27. Plaintiff’s Master Administrative Long-Form Complaint, In re Nat’l 
Football League Players’ Concussion Injury Litig., 307 F.R.D. 351 (E.D. Pa. 2015) 
(No. 2:12-md-02323-AB, MDL No. 2323). 
28. In re Nat’l Football Players’ Concussion Injury Litig., 307 F.R.D. at 
366. The neurological conditions include different levels of neurocognitive 
impairment, Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral 
Sclerosis, and death with CTE. Id. The settlement also includes $10 million for 
education about concussions. Id. at 368-69. A $75 million fund provides eligible 
retired players with baseline assessment examinations of their neurological 
functioning and cognitive decline. Id. at 368. About 200 players have opted out of 
the settlement. Id. at 369. 
29. In re NCAA Student-Athlete Concussion Injury Litig., No. 13-C-9116, 
MDL No. 2492, 2014 U.S. Dist. LEXIS 174334, at *6 (N.D. Ill. Dec. 17, 2014). 
30. In re Nat’l Hockey League Players’ Concussion Injury Litig., MDL No. 
14-2551, 2015 BL 82307, at *2 (D. Minn. Mar. 25, 2015).  
31. Class Action Complaint, Mehr v. Fédération Internationale de Football 
Ass’n, No. 14-cv-3879, 2015 WL 4366044 (N.D. Cal. July 16, 2015). 
32. Haynes v. World Wrestling Entm’t Inc., No. 3:14-cv-01689-ST, 2015 
BL 203505, at *1-2 (D. Or. June 25, 2015). 
33. See Class Action Complaint, Bukal v. Illinois High School Ass’n, No. 
2014-CH-19131 (Cook Cty. Cir. Ct., Ill., Dec. 1, 2014) (alleging that the association 
did not do enough to protect players from concussions). These claims are likely to 
grow. See Michael Tarm, High School Head Injury Lawsuit Filed, HUFFINGTON 
POST (Dec. 18, 2014), http://www.huffingtonpost.com/2014/11/30/high-school-
head-injury-l_n_6245374.html. The attorney who filed the class action lawsuit 
against the NCAA says that his “goal is to bring the fight to the high school level.” 
Sara Ganim, Class-Action Lawsuit Filed over High School Football, CNN (Dec. 2, 
2014), http://www.cnn.com/2014/12/01/us/concussion-lawsuit-high-school-football.  
34. Adam Caplan, NFL Levies Huge Fines for Hits to Head, FOX SPORTS
(June 2, 2014, 1:48 PM), http://www.foxsports.com/nfl/story/helmet-fines-James-
Harrison-Dunta-Robinson-Brandon-Meriweather-101910 [http://http://web.archive. 
org/web/20150526193403/http://www.foxsports.com/nfl/story/helmet-fines-James-
Harrison-Dunta-Robinson-Brandon-Meriweather-101910?]. 
35. See supra note 33. 
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youth football organizations36 have already introduced new policies 
on concussions and increased the penalties for helmet-to-helmet hits.  
Recognizing the epidemic of acquired brain injury is just part 
of the problem; understanding and diagnosing the injury itself 
presents enormous challenges. Unlike the readily apparent nature of 
certain injuries like broken bones or torn skin, brain injury is subtle 
and generally not obvious to an untrained observer. The human brain 
can be injured in many ways,37 and the type of brain injury that 
results from hits to the head, or acquired brain injury, can occur in 
numerous ways as well—from a single major impact (such as a car 
accident or wartime blast) or from lesser but frequent impacts (such 
as football tackles).38
Diagnosing an mTBI is particularly difficult.39 Although there 
are some objective measures to assist in the diagnosis of mTBIs, in 
the end, it remains currently a clinical diagnosis based mainly on 
self-reported symptoms.40 The symptoms vary among individuals 
and may manifest at different times.41 The ability to diagnose CTE is 
limited as well; we do not yet have an objectively verifiable 
neurocognitive measurement for diagnosis and prognosis of CTE 
with an established link to acquired brain injury. Epidemiological 
studies have associated repetitive head injuries to Alzheimer’s, 
Parkinson’s, and Amyotrophic Lateral Sclerosis (ALS) diseases as 
well as CTE,42 but that does not definitively answer whether an 
individual suffers from those diseases as a result of head injuries or 
other risk factors.  
The methodology for diagnosis of mTBIs and CTE is changing, 
however, as scientists are starting to discover and develop tools to 
                                                     
36. Rule Changes Regarding Practice & Concussion Prevention, POP 
WARNER (June 13, 2012), http://www.popwarner.com/About_Us/Pop_Warner_News/ 
Rule_Changes_Regarding_Practice___Concussion_Prevention_s1_p3977.htm. 
37. Brain damage can occur from in utero to the end of life and can result 
from strokes, infections, tumors, and toxins, among other things. See Christina 
Kwasnica et al., Congenital and Acquired Brain Injury. 3. Spectrum of the Acquired 
Brain Injury Population, 89 Supplement 1 ARCHIVES PHYSICAL MED.
REHABILITATION S15-20 (2008). 
38. Id. at S17-18.  
39. See Raquel C. Gardner & Kristine Yaffe, Epidemiology of Mild 
Traumatic Brain Injury and Neurodegenerative Disease, 66 MOLECULAR &
CELLULAR NEUROSCIENCE 75, 76 (2015) (reviewing diagnostic criteria for mTBI). 
40. Id. 
41. See L. Syd M. Johnson, Sport-Related Neurotrauma and 
Neuroprotection: Are Return-to-Play Protocols Justified by Paternalism?, 8
NEUROETHICS 15, 19 (2015). 
42. See Gardner & Yaffe, supra note 39, at 78.  
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detect the subtle damage that occurs when individual molecules are 
disturbed by brain injury.43 Scientists expect this research to lead to 
objective measures—biological markers or “biomarkers”—of these 
acquired brain injuries in the living brain.44 They seek to identify 
biomarkers of effect and susceptibility. For biomarkers of effect, 
scientists hope to develop novel techniques to understand exactly 
how the brain is damaged and how it might be repaired.45 The aim is 
that these biomarkers will not only signal the presence of a 
concussion, but also the extent of it. The objective is also to detect 
the continued presence of the concussion even when outward
symptoms have disappeared.46 Similarly, the goal is that biomarkers 
can be used to detect long-term effects such as CTE, rather than 
waiting for the definitive test from an autopsy.47 For biomarkers of 
susceptibility, scientists hope to determine whether certain people are 
more susceptible to suffering concussions and CTE.48 The difficulties 
that inhere in the current approach to diagnosis of concussive injury, 
as well as the advances in biomarker research that may change that 
approach, are discussed in Part I.  
Developing biomarkers of effect and susceptibility for 
concussive injury will have enormous legal and policy implications. 
This is the focus of Part II. The scientific developments will 
challenge courts and policymakers to rethink when civil liability 
should be imposed, how brain injury cases are litigated, and when 
and how governments should regulate social activity in efforts to 
reduce the incidence and harms of brain injury. These questions are 
examined in the context of youth sports.  
Part II specifically examines how development of biomarkers 
of effect will transform the duty of care of those involved in youth 
sports, including schools, private leagues, trainers, coaches, parents, 
and the players themselves, leading to an overall increase of 
concussive management duties. The change will be implemented on 
two levels—both through common law duties as well as in 
legislation aimed at concussive management. Not only will 
expectations regarding timely and accurate diagnosis of concussive 
                                                     
43. Linda Papa et al., Systematic Review of Clinical Studies Examining 
Biomarkers of Brain Injury in Athletes After Sports-Related Concussion, 32 J.
NEUROTRAUMA 661, 669 (2015). 
44. Id.
45. Id.
46. See infra Subsection II.A.1.c. 
47. See infra Subsection I.C.2. 
48. See infra Subsection I.C.3. 
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injury increase, but a commensurate increase in the duties to both 
avoid and mitigate risks, including an increase in screening and 
monitoring duties, will occur as well. Availability of biomarkers of 
effect will fundamentally change the way the elements of causation 
and injury are proved and may be used by both plaintiffs and 
defendants as objective evidence to prove or disprove those 
elements. These biomarkers will give us greater understanding of 
disease progression and may also lead to recognition of earlier 
claims for subclinical injuries revealed by those biomarkers. 
Biomarkers of anticipated long-term effects, such as CTE, will raise 
the specter of latent injury claims, which are based on the premise 
that a plaintiff has incurred an injury that puts him or her at increased 
risk of future disease. These types of claims often seek recovery for 
medical monitoring or emotional harm, but remain controversial 
because of their speculative nature and the fear of limitless liability. 
Biomarkers will make these claims less speculative.  
Part II also considers how development of biomarkers of 
susceptibility will have an impact on the duties owed to players, as 
well as the duty the player owes to himself or herself. The 
development of these biomarkers will likely generate a duty for 
schools and other sports sponsors to screen and possibly to exclude 
those individuals with susceptibility biomarkers from participating in 
those sports. At a minimum, it will likely engender duties to monitor 
them more closely, provide accommodations, and implement 
additional preventive measures. Screening will also raise significant 
privacy issues, since releasing results of susceptibility screening to 
third parties—such as parents, insurance companies, and 
employers—can have a broad, long-term impact. The duty to inform 
of risks, as well as the ability to accept those risks in play, will also 
be transformed. 
Part III concludes that the development of biomarkers of effect 
and susceptibility will transform the legal landscape of concussive 
injury, both from a public policy and a litigation perspective. 
Examination of these issues requires both a deep understanding of 
the science involved and an explication of the theoretical basis and 
purpose of tort claims and recovery. Given the anticipated increased 
accuracy in diagnosis, prognosis, and cessation of injury, as well as 
susceptibility to injury, the availability of biomarkers should lead to 
a more accurate and just result in litigation. At the same time, 
development of biomarkers may open the door to requiring more 
demanding evidence in court. At the meta-level, the combination of 
the medical and legal applications of mTBI biomarkers will 
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hopefully lead to fewer injuries and safer practices in sports and 
elsewhere, but it is sure to cause significant disruption and risk 
exposure to sports teams, employers, the military, and product 
manufacturers. 
I. CONCUSSIVE INJURY
A. Defining and Diagnosing Brain Injuries 
Traumatic brain injury occurs when an external force, such as 
impact or rapid acceleration or deceleration, causes damage to the 
brain.49 Although research on acquired brain injury continues to 
advance, a single, universal definition of TBI has yet to be 
determined. Aside from being caused by an external source, the 
definition can encompass various scenarios. The damage can be 
focal (occurring at the local site of impact with neurological effects 
specific to the area affected) or diffuse (often delayed and 
widespread).50 It can be based on a direct or indirect blow to the 
head, with a sudden acceleration to the brain.51 It can be a closed 
head injury or penetrating head injury (when an object pierces the 
skull).52 It can be from a single blow or a series of smaller repeated 
impacts. Scientists seek to develop a consensus in diagnosing and 
treating TBI as awareness of the injury increases in both the public 
as well as the medical field.  
To understand acquired brain injury, a brief overview of the 
biomechanics involved is useful. The brain is made of soft tissue and 
is cushioned by spinal fluid and encased in the protective shell of the 
skull.53 The brain tissue is often described as a “Jell-O-like”
substance.54 When an individual sustains trauma, the impact to the 
head can jolt the brain and cause it to move around within the skull 
and even make contact with it. These shocks to the brain can result in 
                                                     
49. See Sarah Malanowski & Nicholas Baima, On Treating Athletes with 
Banned Substances: The Relationship Between Mild Traumatic Brain Injury, 
Hypopituitarism, and Hormone Replacement Therapy, 8 NEUROETHICS 27, 28 
(2015).  
50. Decuypere & Klimo, supra note 21, at 941-42.
51. Id.
52. Id. at 941. 
53. See Y. King Liu, Biomechanics of “Low-Velocity Impact” Head Injury,
in THE EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY 49, 58 
(Nils R. Varney & Richard J. Roberts eds., 1st ed. 1999). 
54. See, e.g., id.  
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chemical changes in nerve cells, mechanical disruption of axons, 
changes in brain blood flow, and neuro inflammation.55
Fundamentally, the brain uses neurons (or nerve cells) to 
communicate with different systems of the brain. All neurons have 
three main parts: (1) the cell body; (2) the axon; and (3) the 
dendrites.56 Much of the recent research on brain trauma focuses on 
axons.57 Axons, which exit the cell body, are used to communicate 
with other neurons through nerve impulses.58 Axons extend across 
the different layers of brain tissue—from gray matter (cerebral 
cortex) to white matter (subcortical area)—to connect the neurons in 
both areas.59 When there is trauma to the brain, the different layers of 
the brain slide across each other, which causes unnatural stresses on 
the axons.60 Research reveals that stretching or tearing an axon 
causes the nerve impulse not to transmit or to transmit less 
efficiently.61 Common cognitive deficits caused by the damaged 
axons are attention and concentration difficulties, fatigue, and 
impaired short-term memory.62
The terms “concussion” and “mTBI” are often used 
interchangeably,63 although mTBI is considered by some to be a 
broader term than concussion.64 Medical diagnosis of acquired brain 
trauma usually distinguishes between severe and mild TBIs.65 This 
                                                     
55. Douglas H. Smith & David F. Meaney, Axonal Damage in Traumatic 
Brain Injury, 6 NEUROSCIENTIST 483, 484-87 (2000); Esteban Toledo et al., The 
Young Brain and Concussion: Imaging as a Biomarker for Diagnosis and 
Prognosis, 36 NEUROSCIENCE & BIOBEHAVIORAL REVS. 1510, 1513-14 (2012). 
56. See HARVEY LODISH ET AL., MOLECULAR CELL BIOLOGY § 21.1 (4th ed. 
2000). 
57. See Douglas H. Smith, Ramona Hicks & John T. Povlishock, Therapy 
Development for Diffuse Axonal Injury, 30 J. NEUROTRAUMA 307, 307 (2013). 
58. See MICHAEL S. GAZZANIGA, RICHARD B. IVRY & GEORGE R. MANGUN,
COGNITIVE NEUROSCIENCE: THE BIOLOGY OF THE MIND 24-28, 60 (2d ed. 2002). 
59. See id. at 64-66.  
60. Smith & Meaney, supra note 55, at 484-87. 
61. See id.  
62. See Fumihiko Yasuno et al., Decision-Making Deficit of a Patient with 
Axonal Damage After Traumatic Brain Injury, 84 BRAIN & COGNITION 63, 63 
(2014). 
63. The terms “concussion” and “mTBI” are used interchangeably in the 
literature and are often treated as synonymous. See Paul McCrory et al., Consensus 
Statement on Concussion in Sport: The 4th International Conference on Concussion 
in Sport Held in Zurich, November 2012, 47 BRIT. J. SPORTS MED. 250, 250 (2013).  
64. See Harmon et al., supra note 1, at 16-17 (“[A]ll concussions are 
MTBIs, not all MTBIs are concussions.”).
65. Approximately 20% of the TBIs diagnosed each year are classified as 
moderate or severe, and 80% are classified as mild. See Malanowski & Baima, 
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distinction, although widely accepted, is inexact; TBI is considered a 
spectrum, and the precise distinction between the two levels of brain 
injury lacks consensus in both medicine and law. By definition, 
“mild” or “minor” traumatic brain injury will not cause the injured 
survivor to die, but beyond that, the terminology “mild” or “minor”
can be misleading;66 even a “minor” TBI can cause significant 
damage.67 Some definitions distinguish a TBI from mTBI by how 
long a person loses consciousness.68 Yet a person can incur a 
concussive injury and potentially serious long-term consequences 
even without losing consciousness, so consciousness is not a 
requirement for diagnosing an mTBI.  
There is no agreed-upon definition of mTBI or concussion, 
because there is no consensus on objective criteria for defining and 
diagnosing this type of injury.69 Rather, mTBI currently remains a 
subjective clinical diagnosis based primarily on patient history and 
observable behavioral symptoms.70 These symptoms can include 
confusion, lightheadedness, blurred vision, dizziness, ringing in the 
ears, fatigue, nausea, and trouble with memory.71 The person may 
feel dazed and have a vacant stare.72 Sometimes, but not always, 
there is loss of consciousness.73 The symptoms often resolve within 
                                                                                                               
supra note 49, at 128. Scientists further break down this dichotomy into four 
categories—mild, moderate, severe, and vegetative state. See infra notes 114-17 and 
accompanying text; Glasgow Coma Scale, TRAUMATIC BRAIN INJ.,
http://www.traumaticbraininjury.com/symptoms-of-tbi/glasgow-coma-scale (last 
visited Feb. 13, 2016); Traumatic Brain Injury: Hope Through Research, NAT’L
INST. NEUROLOGICAL DISORDERS & STROKE, http://www.ninds.nih.gov/disorders/ 
tbi/detail_tbi.htm#266623218 (last visited Feb. 13, 2016). 
66. Semyon Slobounov et al., Sports-Related Concussion: Ongoing Debate,
48 BRITISH. J. SPORTS MED. 75, 75 (2014) (“[T]here is nothing mild about mTBI at 
the cellular level.” (emphasis omitted)).
67. Smith, Hicks & Povlishock, supra note 57, at 313. 
68. See, e.g., CDC, Addressing Critical Gaps, supra note 21, at 17 (defining 
loss of consciousness of thirty minutes or less as “mild,” thirty minutes to twenty-
four hours as “moderate,” and greater than twenty-four hours as “severe”).
69. See Toledo et al., supra note 55, at 1511; Richard P. Dutton et al., 
Diagnosing Mild Traumatic Brain Injury: Where Are We Now?, 70 J. TRAUMA 554, 
554 (2011). The International Conference on Concussion in Sport periodically 
publishes a consensus statement revising its definition of concussion. See McCrory 
et al., supra note 63, at 250.  
70. Dutton et al., supra note 69, at 554.  
71. Id. at 554; Jonathan C. Edwards & Jeffrey D. Bodle, Causes and 
Consequences of Sports Concussion, 42 J.L. MED. ETHICS 128, 128 (2014). 
72. Edwards & Bodle, supra note 71, at 128.  
73. Id. 
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minutes to days74 after a concussion, but in some cases there are 
more enduring symptoms such as persistent headaches, sleep 
disturbance, poor attention and concentration, irritability, and 
depression that can last for several weeks or longer.75 It is not 
surprising that this spectrum of symptoms exists, considering the 
diverse ways in which a brain injury can happen, as well as the 
different brain structures that could be affected by the external 
trauma.  
Mild TBIs do not show up on standard imaging studies, such as 
a CT scan or MRI, since the injuries are typically not structural 
injuries to the brain, but rather, are functional problems caused by 
swelling or bruising.76 Sometimes the injured person can appear 
“normal.” Moreover, some symptoms are evident immediately; 
others surface days or even weeks later,77 and it has become clear 
that some head injuries occur that have no immediate cognizable 
symptoms, which are now classified as subconcussions.78 As noted 
earlier, there is no universally accepted definition of concussion.79
The accuracy of identifying mTBIs and determining whether an 
individual is fully recovered is critical. Most significantly, the risk of 
severe injury can increase with repeated concussions, producing a 
rare, and sometimes disputed, phenomenon referred to as the Second 
                                                     
74. Harmon et al., supra note 1, at 17 (noting that 80%-90% of athletes 
have symptom resolution within seven days of injury). 
75. Id. at 24.
76. McCrory et al., supra note 63, at 250-51 (“Concussion may result in 
neuropathological changes, but the acute clinical symptoms largely reflect a 
functional disturbance rather than a structural injury and, as such, no abnormality is 
seen on standard structural neuroimaging studies.”); see also Erica D. Bruce et al., 
Neuroimaging and Traumatic Brain Injury: State of the Field and Voids in 
Translational Knowledge, 66 MOLECULAR & CELLULAR NEUROSCIENCE 103, 104 
(2015) (presenting evidence that CT imaging is not generally effective for mTBI, 
but may be effective in identifying severe cases of TBI). 
77. See Omalu et al., American Wrestler, supra note 13, at 132 (discussing 
an autopsy report stating that visual examination of the brain showed no sign of 
trauma, and trauma was only visible under microscopic examination). 
78. Thomas W. McAllister et al., Effect of Head Impacts on Diffusivity 
Measures in a Cohort of Collegiate Contact Sport Athletes, 82 NEUROLOGY 63, 66 
(2014) (finding a relationship between magnitude and timing of head impacts and 
effects on white matter in brains of athletes who had no reported concussions). 
79. See Annette Greenhow & Jocelyn East, Custodians of the Game: 
Ethical Considerations for Football Governing Bodies in Regulating Concussion 
Management, 8 NEUROETHICS 65, 69 (2015) (listing differences in approaches, such 
as whether it is a “head injury” or a “brain injury”; whether it is a functional issue or 
structural injury; whether it is an mTBI; and the extent of the association between 
head trauma and long-term cognitive issues).  
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Impact Syndrome.80 Furthermore, therapy for brain repair is 
controversial; the type of care the individual should receive during 
recuperation is not agreed upon.81 Some doctors prescribe brain 
silence (no reading, no math, no computers), while others say some 
brain stimulation is therapeutic.82 Some researchers suggest that 
treatment may depend on what part of the brain received the 
trauma.83 And even harder is determining whether chronic brain 
damage has occurred (and its cause) or whether certain individuals 
might be more susceptible, as discussed below.  
B. Defining CTE 
CTE is a progressive chronic neurodegenerative disease 
associated with a person sustaining repeated blows to the head84 with 
                                                     
80. See Tareg Bey & Brian Ostick, Second Impact Syndrome, 10 W. J.
EMERGENCY MED., 6, 6-7 (2009). Because of the difficulties inherent in collecting 
data on this type of injury, some scientists challenge the diagnosis of Second Impact 
Syndrome. See, e.g., Paul R. McCrory & Samuel F. Berkovic, Second Impact 
Syndrome, 50 NEUROLOGY 677, 679-83 (1998) (challenging the clinical support as 
insufficient to establish Second Impact Syndrome as a risk factor for cerebral 
swelling). However, most scientists agree that risk of exacerbated injury increases
with subsequent impact before one is fully recovered. See Matthew P. MacFarlane & 
Thomas C. Glenn, Neurochemical Cascade of Concussion, 29 BRAIN INJ. 139, 147-
49 (2015) (acknowledging the potential controversy, but nonetheless supporting that 
successive injuries have shown cumulative effect, and cautioning about the risk of 
Second Impact Syndrome, particularly among the younger population). 
81. See Meier & Ivory, supra note 24. 
82. See Lester Mayers, Return-to-Play Criteria After Athletic Concussion: 
A Need for Revision, 65 ARCHIVES NEUROLOGY 1158, 1158, 1160-61 (2008). 
83. Id. at 1160 (outlining that some studies have identified portions of the 
brain that showed abnormalities thirty days post-injury, suggesting a need to 
consider location of injury in recovery timing). 
84. What is CTE?, BU CTE CTR., http://www.bu.edu/cste/about/what-is-cte 
(last visited Feb. 13, 2016). Scientists of the BU Center, through dozens of case 
studies involving deceased athletes whose brains exhibit the distinct tau pattern of 
CTE, have concluded that there is a “clear environmental etiology” and that 
“repetitive mild traumatic brain injury” may cause CTE. See, e.g., Johnson, supra 
note 41, at 16. Not everyone agrees: The 2013 Zurich consensus statement on 
concussion in sport finds such a conclusion speculative and states that the causal 
link between concussive injury and CTE “remains unproven.” See McCrory et al., 
supra note 63, at 254. Critics point to the lack of epidemiological studies and 
evidence that deals with the roles of other factors, such as genetic vulnerability, 
alcohol, drug use, and risky behaviors outside of sports. Brad Partridge & Wayne 
Hall, Repeated Head Injuries in Australia’s Collision Sports Highlight Ethical and 
Evidential Gaps in Concussion Management Policies, 8 NEUROETHICS 39, 41 
(2015). The link between CTE and concussion injury is still being debated. See
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a group of symptoms that include memory loss; movement disorders, 
including Parkinson’s disease; and mood disorders, aggressive or 
violent behaviors, depression, suicidality, substance abuse, and 
cognitive decline.85 Most athletes who have suffered concussions go 
on to live normal, apparently healthy lives, so it is not clear why 
some individuals develop CTE and others do not.86 Repeated head 
trauma seems to be a key risk factor, as the condition was originally 
known by the name of “punch drunk syndrome” and associated with 
boxers,87 but has now been found in others with a history of repeated 
brain trauma.88 Although it is not yet clear whether CTE is a 
signature disease that is specific to repetitive head injuries, autopsy 
research on CTE suggests this possibility.89 CTE manifests 
symptoms similar to those found in Alzheimer’s90 and can take years 
or even decades after the brain trauma has occurred to manifest.91
Researchers suggest that CTE results in progressive cognitive 
decline and aberrant behavior in affected individuals. As one 
researcher noted, “[t]he progression of neurological impairment seen 
in athletes diagnosed post-mortem with CTE suggests that it is 
                                                                                                               
Frédéric Gilbert, State of the Concussion Debate: From Sceptical to Alarmist 
Claims, 8 NEUROETHICS 47, 47 (2015).  
85. What is CTE?, supra note 84 (defining CTE as a “progressive 
degenerative disease of the brain found in athletes (and others) with a history of 
repetitive brain trauma, including symptomatic concussions as well as asymptomatic 
subconcussive hits to the head”). 
86. Edwards & Bodle, supra note 71, at 132. 
87. Harrison S. Martland, Punch Drunk, 91 JAMA 1103, 1103-05 (1928). 
88. Gilbert, supra note 84, at 47 (acknowledging that symptoms of this 
disorder have been observed across multiple sports platforms where participants are 
at risk for repeated head injury and exploring how that risk is interpreted); Bennet I. 
Omalu et al., Chronic Traumatic Encephalopathy in a National Football League 
Player: Part II, 59 NEUROSURGERY 1086, 1087 (2006); Bennet I. Omalu et al., 
Chronic Traumatic Encephalopathy in a National Football League Player, 57 
NEUROSURGERY 128, 129 (2005) [hereinafter Omalu et al., National Football 
League Part I].
89. Assuming that a causal relationship is established, the injury 
threshold—the number and types of trauma to the brain—will also need to be 
determined. See, e.g., Ann C. McKee et al., The Spectrum of Disease in Chronic 
Traumatic Encephalopathy, 136 BRAIN 43, 61-62 (2013). 
90. Id. at 60.  
91. Some recent research suggests that CTE can also develop over only a 
few years. Christine Baugh et al., Chronic Traumatic Encephalopathy: 
Neurodegeneration Following Repetitive Concussive and Subconcussive Brain 
Trauma, 6 BRAIN IMAGING BEHAV. 244, 252 (2012); see also Benoit C. Mouzon et 
al., Chronic Neuropathological and Neurobehavioral Changes in a Repetitive Mild 
Traumatic Brain Injury Model, 75 ANNALS NEUROLOGY 241, 250-51 (2014) 
(describing mouse study of neurobiological deficits in months following a TBI). 
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inevitable that the capacity for autonomous decision making will 
eventually be impaired in athletes with CTE.”92
CTE can be diagnosed definitively only through autopsy; there 
is currently no available way of diagnosing it in the living brain.93
Although the studies of CTE are not nearly as advanced as those of 
Alzheimer’s disease,94 scientists have discovered that CTE is marked 
by the abnormal buildup of a protein called tau in the brain, a protein 
also associated with Alzheimer’s.95 Importantly, recent research 
suggests that the threshold for developing CTE may be lower than 
previously thought. Subconcussive impacts, ones that do not 
manifest symptoms identified with concussions, may be sufficient to 
develop CTE.96 This is a significant change in the medical field’s
understanding of brain trauma.97 Risk factors for CTE, beyond brain 
trauma, remain unknown.98
                                                     
92. See Johnson, supra note 41, at 17. At this point, it may not be possible 
to determine exactly when that autonomy has been impaired or disappears 
completely. Id. 
93. Omalu et al., National Football League Part I, supra note 88, at 129. 
94. See Robert C. Cantu, Chronic Traumatic Encephalopathy in the 
National Football League, 61 NEUROSURGERY 223, 223-24 (2007) (describing the 
history of CTE research; acknowledging that the prevalence of the problem is 
unknown and “[o]nly an immediate prospective study will determine the true 
incidence of this problem”); Christopher Randolph, Stella Karantzoulis & Kevin 
Guskiewicz, Prevalence and Characterization of Mild Cognitive Impairment in 
Retired National Football League Players, 19 J. INT’L NEUROPSYCHOLOGICAL 
SOC’Y 873, 873 (2013) (noting that the “first attempt to systematically explore late-
life cognitive impairments in retired NFL players” occurred in 2005). 
95. What is CTE?, supra note 84 (explaining that CTE “triggers progressive 
degeneration of the brain tissue, including the build-up of an abnormal protein called 
tau”).
96. Baugh et al., supra note 91, at 245; Brandon E. Gavett, Robert A. Stern 
& Ann C. McKee, Chronic Traumatic Encephalopathy: A Potential Late Effect of 
Sport-Related Concussive and Subconcussive Head Trauma, 30 CLINICS SPORTS 
MED. 179, 184 (2011). 
97. See McKee et al., supra note 89, at 62 (“[F]or some athletes and war 
fighters, there may be severe and devastating long-term consequences of repetitive 
brain trauma that has traditionally been considered only mild.”); Gilbert, supra note 
84, at 51-52 (calling for a precautionary approach to addressing policy change 
despite uncertainty of CTE causation); see also Ray W. Daniel, Steven Rowson & 
Stefan M. Duma, Head Impact Exposure in Youth Football, 40 ANNALS 
BIOMEDICAL ENGINEERING 976, 976 (2012) (demonstrating that even sub-
concussive impacts in youth football practice can produce the same kinds of forces 
as concussive impacts).  
98. Philip H Montenigro et al., Clinical Subtypes of Chronic Traumatic 
Encephalopathy: Literature Review and Proposed Research Diagnostic Criteria for 
Traumatic Encephalopathy Syndrome, 6 ALZHEIMER’S RES. & THERAPY 68, 69 
(2014); McCrory et al., supra note 63, at 257 (“[T]he speculation that repeated 
1928 Michigan State Law Review  2015:1911 
C. Advances in Biomarker Research  
There is a growing recognition that the current approach for the 
diagnosis and prognosis of mTBI, based on a graded-symptoms 
checklist, is ineffective and needs to be replaced by more objective 
biomarkers.99 A “biomarker” is an objective physiological indicator 
of a biological disease, injury state, or disease predisposition.100
Biomarkers may be developed from a blood test, saliva, spinal fluid, 
brain scans, eye tracking, or urine. These biomarkers may measure a 
genetic variant, ribonucleic acid (RNA) levels, a protein, a
metabolite, an image, or any other subclinical marker of disease 
predisposition, status, or progression. Because diagnoses of both 
mTBI and CTE are based largely on self-reported clinical symptoms, 
scientists have been searching for biomarkers associated with those 
injured brain states to allow medicine to move beyond a subjective 
clinical diagnosis.  
Many things can turn up as “markers,” but to be effective, 
measurements of brain injury must demonstrate acceptable levels of 
certainty to warrant sufficient confidence in the test and establish 
scientific validity.101 Biomarkers are likely to be probabilistic rather 
than determinative.102 It is also likely that they will work in 
conjunction with other measures, such as clinical features and patient 
history.103 Biomarkers of effect may interact with biomarkers of 
                                                                                                               
concussion or subconcussive impacts cause CTE remains unproven.”). In addition to 
athletes, CTE has been “found in non-athletes who have experienced repetitive head 
impacts, including epileptics, developmentally disabled individuals who head-bang,” 
“victims of physical abuse,” and military members who have served in combat. 
Montenigro et al., supra, at 68. CTE may have a high incidence of comorbidity with 
other diseases, including Parkinson’s and Alzheimer’s. See McKee et al., supra note 
89, at 61.  
99. Slobounov et al., supra note 66, at 76. 
100. See NCI Dictionary of Cancer Terms, NAT’L CANCER INST.,
http://www.cancer.gov/dictionary?CdrID=45618 (last visited Feb. 13, 2016). The 
National Cancer Institute defines a biomarker as a “biological molecule found in 
blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or 
of a condition or disease. A biomarker may be used to see how well the body 
responds to a treatment for a disease or condition.” Id.  
101. See Linda Papa, Damyan Edwards & Michelle Ramia, Exploring Serum 
Biomarkers for Mild Traumatic Brain Injury, in BRAIN NEUROTRAUMA:
MOLECULAR, NEUROPSYCHOLOGICAL, AND REHABILITATION ASPECTS 301, 301 
(Firas H. Kobeissy ed., 2015). 
102. See id. at 301-02. 
103. See id. at 302, 305. 
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susceptibility such as genetics and previous brain injuries, as well as 
confounding factors such as sex, age, and ethnicity.  
Two fundamental types of error can occur in determining the 
validity of a test involving its accuracy and reliability. The first, 
called a Type I error, or false positive, occurs when the effect that is 
being studied is identified when in fact the effect does not exist.104
The second, called a Type II error, or false negative, occurs when a 
true effect is not detected.105 Establishing acceptable levels of Type I 
and Type II errors is important to determine the validity of a test. 
These levels are related to the sensitivity and specificity of a test. 
Sensitivity is a measure of the proportion of true positives that are 
correctly identified; the fewer the false negatives, the higher the 
sensitivity of the test.106 Specificity measures the proportion of 
negatives that are correctly identified; the fewer false positives the 
test produces, the higher the specificity of the test.107
Setting the levels of acceptable errors is a critical issue in the 
search for biomarkers in concussive injury. Many things can be 
potential “markers” for head trauma, but they are generally not very 
sensitive or specific tests.108 Other limitations exist as well.109 Studies 
of biomarkers tend to be small, with selected subjects, which brings 
selection bias into question.110 And with regard to CTE in particular, 
the subjects may also have other potential risk factors for long-term 
cognitive impairment, which may be hard to separate out.111
Yet even with these limitations in mind, the advances in 
research are real and developing rapidly.112 The search for 
                                                     
104. Type I and II Errors and Significance Levels, COMMON MISTEAKS 
MISTAKES IN USING STATISTICS: SPOTTING AND AVOIDING THEM (May 12, 2011), 
http://www.ma.utexas.edu/users/mks/statmistakes/errortypes.html. 
105. Id.
106. Tze-Wey Loong, Understanding Sensitivity and Specificity with the 
Right Side of the Brain, 327 BMJ 716, 716-17 (2003).
107. Type I and II Errors, supra note 104. 
108. Linda Papa et al., Protein Biomarkers for Mild Traumatic Brain Injury,
in BIOMARKERS OF BRAIN INJURY AND NEUROLOGICAL DISORDERS 221, 222 (Kevin 
K.W. Wang, Zhiqun Zhang & Firas H. Kobeissy eds., 2015). 
109. Imaging such as CT and MRI can find damage when it exists, but these 
tests are typically used to confirm an already strong clinical suspicion or localize the 
problem to a specific brain region. Id. Additionally, CT scanning generally has a low 
sensitivity to detect diffuse injury, and while MRI technology can detect diffuse 
injury, it is often cost-prohibitive for widespread use. Id.  
110. See McKee et al., supra note 89, at 44, 61. 
111. Id. at 61. 
112. Enormous funding has been designated for research into concussive 
injury biomarkers. See, e.g., The Head Health Initiative Overview, HEAD HEALTH 
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biomarkers falls into two main types: (1) biomarkers of effect, which 
indicate if an individual has suffered a concussion and whether it has 
been resolved; and (2) biomarkers of susceptibility, which indicate 
that an individual is at increased risk of suffering from concussive 
injury. Biomarkers of effect are not stable over time, so the timing of 
the test is critical.113 Set forth below are examples of recent research 
on biomarkers of effect that may be used for diagnosis and prognosis 
of concussive injury, including biomarkers of CTE and biomarkers 
of susceptibility to concussive injury. All of these different types of 
biomarkers will have a direct impact on the legal landscape of 
concussive injury.  
1. Biomarkers of Effect 
Biomarkers of effect have the potential to detect mTBIs and 
determine whether the concussion has been resolved. They also have 
the potential to detect CTE and the progression of the disease, which 
will be discussed in the next Subsection. This Subsection reviews 
some recent developments in the biomarker of effect research 
generally.  
As discussed above, TBI is a spectrum. More specifically, it is 
generally considered in four categories: mild, moderate, severe, and 
vegetative state.114 Mild and moderate TBI typically result in 
concussion,115 whereas severe TBI typically results in coma or 
death.116 Researchers have found biomarkers to be accurate in 
                                                                                                               
INITIATIVE, https://ninesights.ninesigma.com/web/head-health/head-health (last 
visited Feb. 13, 2016) (announcing a $22 million investment in biomarker research 
for concussive injury); Department of Defense to Fund $5.5 Million Concussion 
Study, MED. C. WIS., (Dec. 15, 2014), http://www.mcw.edu/MCW-News-Center/ 
College-News/Department-of-Defense-to-fund-5.5-million-concussion-study.htm 
[http://web.archive.org/web/20150910000858/http://www.mcw.edu/MCW-News-
Center/College-News/Department-of-Defense-to-fund-5.5-million-concussion-
study.htm] (announcing the start of a biomarkers study funded by the Department of 
Defense).  
113. Gary E. Marchant, Genetics and Toxic Torts, 31 SETON HALL L. REV.
949, 970 (2001) (referring to genetic biomarkers) [hereinafter Marchant, Genetics 
and Toxic Torts].  
114. See Glasgow Coma Scale, supra note 65. 
115. Sharon M. Valente & Diane Fisher, Traumatic Brain Injury, 7 J. FOR 
NURSE PRAC. 863, 863 (2011). 
116. See Glasgow Coma Scale, supra note 65. The traditional clinical 
diagnostic for distinguishing between mild, moderate, and severe TBI is the 
Glasgow Coma Scale (GCS). Id. GCS scores below 9 indicate more serious injury, 
while 9–12 are considered moderate and 13–15 are considered mild (mTBI). Id.
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identifying severe TBI, including serum-based markers117 as well as 
brain scanning tools, such as computed tomography (CT) and 
magnetic resonance imaging (MRI). Biomarkers that can indicate 
mild injury are especially needed as CT and MRI scans have more 
difficulty detecting these injuries.118
While validated biomarkers of mTBI are not currently 
available, scientists have made rapid progress in recent years in 
developing a number of possible biomarkers.119 Those developments 
                                                     
117. See Emine Meric et al., The Prognostic Value of Neuron-Specific 
Enolase in Head Trauma Patients, 38 J. EMERGENCY MED. 297, 300 (2010) 
(finding increased levels of Neuron-Specific Enolase (NSE) coincide with more 
severe trauma, specifically for lower Glasgow scores indicating severe trauma); 
Yoshinori Yamazaki et al., Diagnostic Significance of Serum Neuron-Specific 
Enolase and Myelin Basic Protein Assay in Patients with Acute Head Injury, 43 
SURGICAL NEUROLOGY 267, 271 (1995) (finding that Myelin Basic Protein (MDP) 
in serum was an accurate marker for severe trauma); Stefania Mondello et al., AII-
Spectrin Breakdown Products (SBDPs): Diagnosis and Outcome in Severe 
Traumatic Brain Injury Patients, 27 J. NEUROTRAUMA 1203, 1206 (2010) (finding 
SBD145 provided detection as early as six hours after injury, while SBDP120 was 
comparable to SBDP145 after seven days from injury).
118. Jonathan T. Finnoff, Elena J. Jelsing & Jay Smith, Biomarkers, 
Genetics, and Risk Factors for Concussion, 3 PM&R 452, 453 (2011). 
119. One problem with these studies is that the biomarker results are tested 
by reference to conventional measures. The biomarkers being developed do not yet 
answer the question whether an individual has suffered a concussion or has CTE; the 
researcher must look to other indicia. Most of the biomarker studies thus far have 
only been validated when compared to controls (without trauma) and those with 
trauma verified by neuropsychological or other conventional testing, which is based 
on clinical observations (whether drawing from subjective reports of the patient, 
observations of neurological symptoms, or results of other tests). See Ali Alawieh et 
al., Neuro-Proteomics and Neuro-Systems Biology in the Quest of TBI Biomarker 
Discovery, in BIOMARKERS OF BRAIN INJURY AND NEUROLOGICAL DISORDERS,
supra note 108, at 21-22 (describing problems with validation in biomarker 
research); Papa et al., supra note 43, at 661 (stating no consensus has yet been 
reached for how to validate biomarkers). While some approaches compare 
biomarkers with the current clinical and observational diagnostic methods, others 
seek to also validate fluid biomarkers against other, non-invasive tests, such as MRI 
data. E.g., Matthew T. McCarthy & Barry E. Kosofsky, Clinical Features and 
Biomarkers of Concussion and Mild Traumatic Brain Injury in Pediatric Patients,
1345 ANNALS N.Y. ACAD. SCI. 89, 93 (2015). 
  In other words, we validate our new tools with our old tools. We have 
not yet reached the point at which these variables are an independent (and 
presumably more dependable) measure. This is new research, and we need further 
longitudinal studies to tie validity to longer term outcomes. Another problem is that 
we have begun to measure physiological changes that have no (or not yet any) 
manifestation in cognition or behavior. Uzma Samadani et al., Sensitivity and 
Specificity of an Eye Movement Tracking-Based Biomarker for Concussion,
CONCUSSION 7, 17 (2015) (stating that biomarker and imaging testing appear to 
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are the focus of this Article, given that these injuries are more 
prevalent than severe TBI among athletes and the military, as well as 
the general population.120 We outline below a few of the more 
prevalent biomarkers that are currently under study.  
S100B, a calcium binding protein that regulates cell 
development and degradation, has some potential as a blood-based 
biomarker of concussive injury.121 It is well documented that elevated 
levels of the S100B protein are present in the blood after brain 
injury.122 In one study, researchers found that S100B levels in serum 
correlated with the severity of TBI and were consistent with the 
results of CT scans,123 but found that S100B levels were less sensitive 
indicators of injury in cases of mTBI.124 In contrast, another study 
suggested that measurement of S100B in serum could accurately 
predict recovery from mTBI.125 Finding some middle ground, a 2013 
                                                                                                               
detect “subclinical” injury, even though the patient continues to have cognitive 
function levels that pass neurocognitive testing procedures). And there is always a 
danger that juries or policy-makers will prefer the evidence of biomarkers over other 
forms of evidence, given our cultural addiction to faith in what is “physical,” 
although other studies suggest otherwise. See Nicholas J. Schweitzer et al., 
Neuroimages as Evidence in a Mens Rea Defense: No Impact, 17 PSYCHOL., PUB.
POL’Y, & L. 357, 366 (2011) (finding no evidence that neuroimaging unduly 
influences juries over verbal, neuroscience-based evidence; neuroscience evidence 
was more effective than clinical psychological evidence but that effect did not 
translate into differences in juries). But while these limitations may be fodder for 
evidentiary challenges or cross-examination, they do not justify an absolute bar to 
using biomarkers in legal or policy decisions. 
120. See Geoffrey T. Manley & Andrew I. R. Maas, Traumatic Brain Injury: 
An International Knowledge-Based Approach, 310 JAMA 473, 473 (2013). 
121. More specifically, S100B is a calcium binding protein that regulates 
protein phosphorylation and degradation, cell growth, and differentiation. See
Valentina Di Pietro et al., S100B and Glial Fibrillary Acidic Protein as Indexes to 
Monitor Damage Severity in an In Vitro Model of Traumatic Brain Injury, 40 
NEUROCHEMICAL RES. 991, 997 (2015).  
122. Stephen M. Bloomfield et al., Reliability of S100B in Predicting 
Severity of Central Nervous System Injury, 6 NEUROCRITICAL CARE 121, 124 
(2007). Higher levels of S100B indicate significant injury, while slightly elevated 
levels may be present from activity such as jogging. Id. at 125. Although it may be 
difficult to determine at what level S100B presence indicates injury, at high levels it 
is highly correlative with injury. Id.  
123. Lynn Babcock et al., Ability of S100B to Predict Severity and Cranial 
CT Results in Children with TBI, 26 BRAIN INJ. 1372, 1378 (2012). 
124. Id. at 1379. In those cases, additional symptoms, such as nausea, were 
useful in determining the severity of the injury prior to a CT scan. Id. at 1378.  
125. WJ Townsend et al., Head Injury Outcome Prediction in the Emergency 
Department: A Role for Protein S-100B?, 73 J. NEUROLOGY NEUROSURGERY 
PSYCHIATRY 542, 544 (2002). The authors found that levels of S100B could 
accurately predict patient outcomes at one month from injury. Id. at 542. 
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study compared S100B accuracy with traditional prognosis 
techniques and found that while S100B was not as accurate in 
determining the severity of injury, the use of S100B along with these 
other prognostic tools created a more effective test than the 
traditional prognostics alone.126
Scientists are studying glial fibrillary acidic protein (GFAP), 
another protein released upon TBI, as a potential biomarker of 
effect.127 Presence of GFAP in serum may indicate intracranial 
hemorrhage and damage to the blood-brain barrier (BBB).128 In a 
2012 study, researchers took serum samples of individuals 
hospitalized for TBI and measured the GFAP levels in the serum.129
The study found that the amount of GFAP in the serum increased 
with the severity of TBI and correlated with more significant injury 
discovered by CT scans.130 The researchers also found that GFAP 
levels were elevated within an hour after injury.131
The human brain can be injured in many ways, and the type of 
injury that results from hits to the head (acquired brain injury) can 
occur in many ways as well—from a lone but powerful impact (such 
as a transportation accident or battlefield injury) or from less 
powerful but more frequent impacts (such as shaken baby syndrome 
                                                     
126. Mehdi Moazzez Lesko et al., Comparison of Several Prognostic Tools 
in Traumatic Brain Injury Including S100B, 28 BRAIN INJ. 987, 991 (2014).
Traditional prognostic tests include CT scans, pupillary reactivity, and Glasgow. Id.
at 987. 
127. See Di Pietro et al., supra note 121, at 996. 
128. Zhifeng Kou et al., Combining Biochemical and Imaging Markers to 
Improve Diagnosis and Characterization of Mild Traumatic Brain Injury in the 
Acute Setting: Results from a Pilot Study, 8 PLOS ONE 1, 10 (2013); Praveen 
Ballabh, Alex Braun & Maiken Nedergaard, The Blood-Brain Barrier: An 
Overview: Structure, Regulation, and Clinical Implications, 16 NEUROBIOLOGY 
DISEASE 1, 1 (2004) (“The blood-brain barrier (BBB) is a diffusion barrier, which 
impedes influx of most compounds from blood to brain.”). Dysfunction of the BBB 
may result in stroke, neuroinflammatory disorders, and other neurologic diseases. 
See id. Authors of a 2013 study measured serum GFAP levels of nine patients with 
mTBI injury and compared these levels with the results of MRIs. Id. at 3. The 
authors found that certain levels of GFAP in serum may indicate bleeding across the 
BBB at small levels beyond MRI detection. Id. at 10.
129. Linda Papa et al., Elevated Levels of Serum Glial Fibrillary Acidic 
Protein Breakdown Products in Mild and Moderate Traumatic Brain Injury Are 
Associated with Intracranial Lesions and Neurosurgical Intervention, 59 ANNALS 
EMERGENCY MED. 471, 471 (2012) (studying 108 individuals).  
130. Id. at 476.  
131. Id.  
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or football tackles).132 One study of patients suffering TBI found that 
UCH-L1 levels were significantly increased in serum six to twenty-
four hours after injury and through the next seven days.133 Another 
study found that UCH-L1 is an accurate marker in mTBI as well.134
Authors of a 2012 study measured levels of UCH-L1 in patients who 
suffered mild and moderate TBI.135 The study found significantly 
higher levels of UCH-L1 compared to the control group, even in 
those with mTBI.136 A separate study found that measuring both 
UCH-L1 and GFAP levels could lead to a highly effective biomarker 
test.137
Total tau (T-tau), a protein secreted by the axons of 
unmyelinated nerve cells when they are injured,138 is another 
potential biomarker of concussion. A study by Dr. Pashtun Shahim 
suggested that the blood levels of T-tau could be used to gauge the 
                                                     
132. Stefania Mondello et al., Clinical Utility of Serum Levels of Ubiquitin 
C-Terminal Hydrolase as a Biomarker for Severe Traumatic Brain Injury, 70 
NEUROSURGERY 666, 666 (2012) [hereinafter Mondello (2012)]; Stefania Mondello 
et al., Neuronal and Glial Markers Are Differently Associated with Computed 
Tomography Findings and Outcome in Patients with Severe Traumatic Brain Injury: 
A Case Control Study, 15 CRITICAL CARE 156, 165 (2011) [hereinafter Mondello 
(2011)]; Linda Papa et al., Serum Levels of Ubiquitin C-Terminal Hydrolase 
Distinguish Mild Traumatic Brain Injury from Trauma Controls and Are Elevated in 
Mild and Moderate Traumatic Brain Injury Patients with Intracranial Lesions and 
Neurosurgical Intervention, 72 J. TRAUMA ACUTE CARE SURGERY 1335, 1343 
(2012).
133. Mondello (2012), supra note 132, at 668-69 (studying ninety-five 
patients). The authors also found the levels of UCH-L1 could be predictive of 
patient survival. Id. at 670 (finding UCH-L1 may predict survival in patients even as 
soon as six hours from injury). 
134. Papa et al., supra note 132, at 1339. 
135. Id. at 1336. They sampled eighty-six patients with mild TBI and ten 
with moderate TBI. Id. at 1337. 
136. Id. at 1338 (finding that levels of UCH-L1 could differentiate between 
control and very mild cases of TBI, including patients with a GCS of 15). 
137. Mondello (2011), supra note 132, at 156. In the 2010 study, researchers 
measured both UCH-L1 and GFAP levels in eighty-one patients with GCS scores of 
8 and lower (severe TBI). Id. They found both biomarkers to be much higher in 
those patients than in the control group. Id. at 158. Interestingly, UCH-L1 levels 
were higher in diffuse injury than mass legion, whereas GFAP levels were higher in 
mass legion than diffuse injury. Id. at 161. While the study did not include patients
with mTBI, it still leads to the conclusion that the two biomarkers are released on 
different biochemical pathways and suggests that the combination of both could 
result in a highly effective biomarker test. Id. at 164.  
138. John Q. Trojanowski et al., Distribution of Tau Proteins in the Normal 
Human Central and Peripheral Nervous System, 37 J. HISTOCHEMISTRY 
CYTOCHEMISTRY 209, 209 (1989). 
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severity of concussions in athletes and to assess when it is safe to 
return to play.139 Measuring blood levels of T-tau to determine brain 
injury is a new concept; Dr. Shahim noted that studies show that T-
tau is usually found only in the cerebrospinal fluid but may get into 
the blood at detectable levels after concussion with axonal injury.140
Dr. Shahim’s study involved 288 professional ice hockey 
players in Sweden.141 The researchers measured serum levels of three
potential biomarkers, all of which have been previously associated 
with brain injury: neuron-specific enolase (NSE), S100B, and T-
tau.142 To create a baseline, the researchers took blood tests from the 
athletes for the three biomarkers at the start of the season.143 Half of 
these players were tested again after a friendly game, in which there 
were no concussions, to assess the effect of exercise.144 Results 
showed that the levels of two of the biomarkers—S100B and NSE—
increased after the friendly match, but there was no change in T-tau 
levels.145
Researchers then measured the T-tau level of players who 
sustained concussions during the season at different times.146 The 
plasma levels of T-tau increased in the concussed hockey players, 
with the highest concentrations immediately after the injury, with a 
second peak between twelve and thirty-six hours later.147
Significantly, the T-tau concentrations at one hour after concussion 
                                                     
139. Pashtun Shahim et al., Blood Biomarkers for Brain Injury in Concussed 
Professional Ice Hockey Players, 71 JAMA NEUROLOGY 684, 684 (2014).  
140. Id. at 690; see Jeffrey Randall et al., Tau Proteins in Serum Predict 
Neurological Outcome After Hypoxic Brain Injury from Cardiac Arrest: Results of a 
Pilot Study, 84 RESUSCITATION 351, 352 (2013). 
141. Shahim et al., supra note 139, at 686. 
142. See M.R. Graham et al., Direct Hits to the Head During Amateur 
Boxing Is Associated with a Rise in Serum Biomarkers for Brain Injury, 24 INT’L J.
IMMUNOPATHOLOGY PHARMACOLOGY 119, 119 (2011); Sanna Neselius et al., 
Olympic Boxing Is Associated with Elevated Levels of the Neuronal Protein Tau in 
Plasma, 27 BRAIN INJ. 425, 426 (2013); Henrik Zetterberg et al., Sustained Release 
of Neuron-Specific Enolase to Serum in Amateur Boxers, 23 BRAIN INJ. 723, 723-24 
(2009). 
143. See Shahim et al., supra note 139, at 685. 
144. Id.  
145. Id. at 686. This result casts doubts on the usefulness of NSE and S100B 
as biomarkers for mTBI. That the levels of both were elevated after a friendly match 
that did not result in a concussion (which was presumably a consequence of exertion 
and bruising of muscles and peripheral tissue) suggests a lack of specificity for brain 
injury. Id. at 690.  
146. Id. at 685. The players’ tau levels were measured at one hour, twelve 
hours, thirty-six hours, six days, and when the athlete returned to play. Id. 
147. Id. at 686-87, 689.  
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predicted the number of days it took for the concussion symptoms to 
resolve.148 T-tau measurements remained significantly elevated in 
players who had suffered a concussion compared with preseason 
levels at all time-points measured in this study, even when the 
concussion symptoms resolved and players were safe to return to 
play.149
These results suggest that serum levels of T-tau may prove to 
be a useful biomarker to diagnose and predict the outcomes of 
concussions among athletes.150 Further studies may show how long it 
takes for plasma T-tau levels to normalize and whether persistently 
elevated levels of plasma T-tau can identify athletes who have 
sustained multiple concussion.151
Scientists from the University of Pennsylvania used the same 
Swedish ice hockey players’ study to investigate a different 
biomarker for potential diagnostic use.152 They found that a blood 
protein called SNTF,153 a protein that is present at undetectable levels 
in healthy human brains but is produced under conditions where 
nerve cells are traumatized and begin to die,154 surged and stayed 
elevated in the professional hockey players with persistent 
concussion symptoms, but not in players whose symptoms subsided 
within a few days.155 The increased levels of SNTF were strongly 
correlated with diffuse axonal injury and long-term cognitive 
dysfunction.156 Other results showed that when used in conjunction 
with the biomarker T-tau, the diagnostic accuracy was improved and 
was more effective than tau alone.157
                                                     
148. Id. at 687, 689. 
149. Id. at 686.  
150. Id. at 689-91.  
151. T-tau levels may also be able to identify individuals who are at risk for 
developing CTE. See infra notes 166-78 and accompanying text.  
152. Robert Siman et al., Serum SNTF Increases in Concussed Professional 
Ice Hockey Players and Relates to the Severity of Postconcussion Symptoms, 32 J.
NEUROTRAUMA 1294, 1294-95 (2015). 
153. Calpain-cleaved alpha-ll-spectrin N-Terminal fragment, or SNTF, is a 
brain-enriched protein. Robert Siman et al., Evidence that the Blood Biomarker 
SNTF Predicts Brain Imaging Changes and Persistent Cognitive Dysfunction in 
MildTBI Patients, 4 FRONTIERS NEUROLOGY 1, 1 (2013).  
154. Siman et al., supra note 152, at 1295. 
155. Id. at 1298. 
156. Id. Researchers concluded that concussions that lead to long-term brain 
dysfunction cause SNTF to accumulate in the axon tracts of the brain, and that 
elevated blood levels of SNTF are a measure of this diffuse axonal injury. Id.
157. Id. at 1299. 
 Biomarkers, Concussions, and the Duty of Care 1937 
Blood serum is not the only area of focus.158 Research in 
ophthalmology also has promising results. Researchers at NYU have 
developed new technology to assess the location and impact of brain 
injury by tracking the eye movements of patients as they watch 
music videos for less than four minutes.159 In the neurologically 
healthy subjects, the ratios of how the eye moved vertically and 
horizontally were close to one to one.160 But in the participants with 
damage in the nerves that move the eyes or with brain swelling 
adjacent to those nerves, all showed abnormal eye movement ratios 
correlating to the nerve that was affected.161 In every case where the 
abnormal eye movement was due to swelling in the brain, surgery to 
correct the brain problem also restored the eye movements to normal 
range.162
There has also been important progress in applying new brain 
scan technologies for detecting mTBI, which as discussed above is 
usually not detected by conventional CT or MRI scans.163
Magnetoencephalography (MEG) is a functional brain imaging 
technique that measures the neuronal current in the grey areas of the 
                                                     
158. Scientists are increasingly seeking to develop minimally invasive or 
non-invasive means of reliably detecting both the presence and severity of 
concussive injury that still rely on biological systems and are considered types of 
biomarkers. Measuring a subject’s movement and balance is one recent development 
that shows potential. See Jasper O. Chang et al., An Alternative to the Balance Error 
Scoring System: Using a Low-Cost Balance Board to Improve the 
Validity/Reliability of Sports-Related Concussion Balance Testing, 24 CLINICAL J.
SPORT MED. 256, 261 (2014).  
159. Uzma Samadani et al., Detection of Third and Sixth Cranial Nerve 
Palsies with a Novel Method for Eye Tracking While Watching a Short Film Clip,
122 J. NEUROSUGERY 707, 708-09 (2015).  
160. Id. at 709. 
161. Id. at 709-15. 
162. Id. at 707, 709-17. In a subsequent study, researchers tracked eye 
movement of seventy-five trauma subjects and sixty-nine non-injured control 
subjects. Uzma Samadani et al., Eye Tracking Detects Disconjugate Eye Movements 
Associated with Structural Traumatic Brain Injury and Concussion, 32 J.
NEUROTRAUMA 548, 549 (2015). As in the previous study, subjects with abnormal 
results gradually returned to baseline values during the follow-up period with 
recovery. Id. at 551. Results indicated that measures of horizontal disconjugacy were 
significantly increased in the trauma patients relative to the control group. Id. at 550-
51. These findings suggest that methods such as eye tracking may prove to be 
consistently more sensitive to detecting brain injury than the currently employed 
methods of CT scan or observation by simple finger or pen-light tracking 
administered by a physician. 
163. See Bruce et al., supra note 76, at 103-04; Erin D. Bigler, 
Neuroimaging Biomarkers in Mild Traumatic Brain Injury (mTBI),
23 NEUROPSYCHOLOGY REV. 169, 170 (2013).  
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brain that in one study was able to accurately diagnose over 80% of 
mTBI patients, compared to less than 10% for MRI scanning for the 
same patients.164 Several other neuroimaging modalities are also 
being investigated for providing biomarkers of mTBI.165
2. Biomarkers of CTE 
Researchers have focused on a number of potential biomarkers 
for CTE.166 In particular, they have focused on the abnormal tangles 
of neural protein tau that accumulate in neurons of brains of 
individuals with CTE and with Alzheimer’s, and which can be 
measured using brain-imaging technologies in living patients.167 A
recent study involved fourteen retired NFL football players, all of 
whom had sustained at least one concussion, and with various 
degrees of suspected CTE.168 Their results were compared with 
participants with healthy brains and participants who met the 
standard diagnostic criteria for Alzheimer’s.169
The researchers scanned the brains of participants using 
Positron Emission Tomography (PET)170 after injecting them with a 
specially developed radioactive tracer called [F-18] FDDNP, which 
binds to deposits of the tau.171 Using these PET scans, the researchers 
were able to pinpoint where in the brain these abnormal proteins 
accumulated. They found that the imaging pattern in people with 
suspected CTE differs significantly from healthy volunteers and 
                                                     
164. Ming-Xiong Humang et al., Single-Subject-Based Whole-Brain MEG 
Slow-Wave Imaging Approach for Detecting Abnormality in Patients with Mild 
Traumatic Brain Injury, 5 NEUROIMAGE: CLINICAL 109, 115 (2014). 
165. Bigler, supra note 163, at 171-74; Toledo et al., supra note 55, at 
1519-23.
166. Montenigro et al., supra note 98, at 2. 
167. Jorge R. Barrio et al., In Vivo Characterization of Chronic Traumatic 
Encephalopathy Using [F-18]FDDNP PET Brain Imaging, 112 PROC. NAT’L ACAD.
SCI. E2039, E2039, E2044 (2015). This research built on preliminary work 
published in 2013. Gary W. Small et al., PET Scanning of Brain Tau in Retired 
National Football League Players: Preliminary Findings, 21 AM. J. GERIATRIC 
PSYCHIATRY 138 (2013). 
168. Barrio et al., supra note 167, at E2040.
169. Id. at E2041. 
170. PET is an imaging technique, similar to MRI or CT, that “allows the 
non-invasive detection and quantification of proteins linked to disease.” David T. 
Chien et al., Early Clinical PET Imaging Results with the Novel PHF-Tau 
Radioligand [F18]-T808, 38 J. ALZHEIMER’S DISEASE 171, 171 (2014). 
171. Barrio et al., supra note 167, at E2040.
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those with Alzheimer’s.172 The researchers identified four distinctive 
patterns of tau tangles in the brains of the former football players that 
did not appear in the normal brains of the controls in the study. In 
particular, they found that the former athletes had higher levels of 
FDDNP in the amygdala and subcortical regions of the brain.173 The 
researchers suggested that these patterns mimic the damage that 
occurs from a concussion, starting in the midbrain, moving toward 
the subcortical areas and amygdala, and then advancing to the 
cerebral cortex.174 In contrast, the tau tangles in the brains of the 
Alzheimer’s-diagnosed participants appeared to start in the cerebral 
cortex.175
The study was small and not without controversy.176 There have 
been a small number of other studies using PET or other brain 
imaging technologies that have differentiated CTE from Alzheimer’s
in living, at-risk individuals.177 These findings indicate a promising 
                                                     
172. Id. at E2044. 
173. Id. at E2043-44. 
174. Id. at E2045-46. 
175. Id. at E2044. Researchers intend to expand the study to determine 
whether there is a “blast variant” version of CTE. Id. at E2045-46.  
176. A panel of experts convened by the National Institute of Neurological 
Disorders and Stroke concluded that the pathological signature of CTE is found in 
the cerebral cortex. Report from the First NIH Consensus Conference to Define the 
Neuropathological Criteria for the Diagnosis of Chronic Traumatic 
Encephalopathy, NAT’L INST. HEALTH, http://www.ninds.nih.gov/research/tbi/ 
ReportFirstNIHConsensusConference.htm (last updated Mar. 31, 2015). 
Furthermore, some of the lead scientists on the study charged several former NFL 
players with suspected CTE a fee to get a PET scan with their FDDNP tracer, which 
led to a warning from the FDA because FDDNP has not been approved for clinical 
use. Ken Belson, Researchers Seeking to Find a Brain Disease in Living Patients 
Are Under F.D.A. Scrutiny, N.Y. TIMES, Apr. 12, 2015, at SP4. The PET scans cost 
about $10,000 to administer. Id.
177. Christine M. Baugh et al., Current Understanding of Chronic Traumatic 
Encephalopathy, 16 CURRENT TREATMENT OPTIONS NEUROLOGY 306, 313 (2014).
[F18]-T808 is another tau-specific ligand biomarker researchers have found that 
may be detected with PET imaging. Id. at 314. While this study used [F18]-T808 
detection as an indicator of Alzheimer’s disease, it could be useful in detecting other 
tauopathy neurodegenerative diseases, including CTE. Chien et al., supra note 170,
at 171; Baugh et al., supra note 91, at 251. 
  Diffusion tensor imaging (DTI) is another imaging technique that may 
prove useful. Michael H. Chappell et al., Distribution of Microstructural Damage in 
the Brains of Professional Boxers: A Diffusion MRI Study, 24 J. MAGNETIC 
RESONANCE IMAGING 537, 537 (2006). DTI differs from MRI or CT imaging 
because it is sensitive to diffusion (molecules traveling across areas of differing 
concentrations), making it sensitive to microstructural changes. Id. Detecting these 
microstructural changes may give insight to brain injury that other imaging 
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way to diagnose CTE in the living brain, but more validation is 
needed before they can be used to diagnose CTE reliably in living 
patients.178 This may require long-term, longitudinal epidemiological 
studies.179  
While there are fewer studies regarding in vivo biomarkers for 
CTE than TBI, research of bodily fluid biomarkers in TBI and mTBI
may also prove useful in diagnosing CTE.180 Researchers have found 
that various biomarkers are expressed for differing periods of time 
after injury. In a 2012 study, researchers found that levels of 
neurofilament light protein and GFAP were elevated in the cerebral 
spinal fluid of amateur boxers two weeks after a bout.181 In another 
study, the investigators measured the NSE levels in serum of amateur 
boxers who spent two months without boxing182 and found those 
boxers still had higher levels of NSE compared to controls.183 These 
biomarkers that are still expressed weeks and months after injury 
(and may be prolonged in those with prior injury) have potential for 
diagnosing CTE in the living brain.184 Thus, repeat measurements of 
markers that have previously been used to diagnose mTBI and TBI 
may be useful in identifying individuals at higher risk for developing 
                                                                                                               
techniques cannot. Id. In a study of eighty-one professional boxers, researchers 
found certain abnormalities in the brain shown by DTI indicated damage due to the 
boxer’s history. Id. at 538. These abnormalities were present even if the subject had 
no history of major trauma, suggesting that DTI may be useful in detecting CTE in a 
patient without a history of TBI. Id. at 538, 540.  
178. See In re Nat’l Football Players’ Concussion Injury Litig., 307 F.R.D. 
351, 399 (E.D. Pa. 2015) (describing limitations of studies of abnormal tau protein 
in living brains of individuals with histories of repetitive mTBI, including the small 
size of the studies, the bias in the selection of the subjects, and the failure to control 
for other potential risk factors, such as higher weight, lifestyle changes, age, or 
substance abuse).  
179. Id.  
180. Jesse Mez, Robert A. Stern & Ann C. McKee, Chronic Traumatic
Encephalopathy: Where Are We and Where Are We Going?, 13 CURRENT 
NEUROLOGY & NEUROSCIENCE REP. 407, 415 (2013). 
181. Sanna Neselius et al., CSF-Biomarkers in Olympic Boxing: Diagnosis 
and Effects of Repetitive Head Trauma, 7 PLOS ONE 1, 3 (2012). 
182. Zetterberg et al., supra note 142, at 724. 
183. Id. The study noted that the half-life of NSE is only forty-eight hours.
Id. at 725. The same research group found in an earlier study that neurofilament 
light protein levels were elevated in the cerebral spinal fluid even after three months 
resting time. Henrik Zetterberg et al., Neurochemical Aftermath of Amateur Boxing,
63 ARCHIVES NEUROLOGY 1277, 1279 (2006). 
184. Ryan C. Turner et al., Repetitive Traumatic Brain Injury and 
Development of Chronic Traumatic Encephalopathy: A Potential Role for 
Biomarkers in Diagnosis, Prognosis, and Treatment?, 3 FRONTIERS NEUROLOGY 1, 
7 (2013). 
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CTE.185 Since those with a concussive history have almost a six-
times greater risk of future concussive injury, mTBI and TBI 
biomarkers and repeated measurement after injury could help predict 
and diagnose CTE.186
3. Biomarkers of Susceptibility 
Some people may have a genetic or other predisposition to 
concussion and CTE. Although several genetic biomarkers 
potentially may be connected with an increased risk of concussion,187
most of the research has focused on the apolipoprotein E (APOE) 
gene because of its association with Alzheimer’s.188 More 
specifically, research has focused on the ϵ4 allele of the APOE gene, 
which may impose greater concussion risks on carriers of the 
allele.189 Other studies have indicated that the APOE ϵ4 allele may 
contribute to genetic susceptibility of CTE.190
The APOE gene regulates apolipoprotein (Apo E) production. 
Apo E helps lipid transportation in the brain, maintains neural 
structural integrity, and promotes recovery after neural injury.191
Scientists believe that the normal ϵ3 allele promotes neural recovery, 
while ϵ4 inhibits neural growth.192 Some studies have suggested that 
the ϵ4 allele inhibits recovery from TBI and results in a poorer 
patient outcome.193 In one study, those with the ϵ4 allele were found 
to have a worse recovery six months after injury, and those who were 
ϵ4 homozygotes had a significantly higher chance of death resulting 
from their injuries.194 Another study surveyed the results of seventy 
children who suffered TBI and found that the possession of the ϵ4 
allele resulted in worse recovery than children with the ϵ3 / ϵ3 and 
                                                     
185. Id. 
186. Mez, Stern & McKee, supra note 180, at 412. 
187. Cameron B. Jeter et al., Biomarkers for the Diagnosis and Prognosis of 
Mild Traumatic Brain Injury/Concussion, 30 J. NEUROTRAUMA 657, 659 (2013). 
188. Id. at 666; Baugh et al., supra note 91, at 249.  
189. Jeter et al., supra note 187, at 666. 
190. See Mez, Stern & McKee, supra note 180, at 413. 
191. Finnoff, Jelsing & Smith, supra note 118, at 454. 
192. Id.; Graham M. Teasdale et al., Association of Apolipoprotein E
Polymorphism with Outcome After Head Injury, 350 LANCET 1069, 1070 (1997).
193. Finnoff, Jelsing & Smith, supra note 118, at 454; Teasdale et al., supra
note 192, at 1071; Thomas Roland Terrell et al., APOE, APOE Promoter, and Tau 
Genotypes and Risk for Concussion in College Athletes, 18 CLINICAL J. SPORT 
MED. 10, 10-11 (2008). 
194. Teasdale et al., supra note 192, at 1070. 
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ϵ3 / ϵ2 genotypes.195 Other studies have suggested, however, that 
there is no connection between the ϵ4 allele and the frequency of 
mTBI.196 Given these conflicting results, no consensus exists at this 
time on whether Apo ϵ4 is a useful susceptibility biomarker of mTBI 
risk.197 While the evidence suggests that Apo ϵ4 does not increase the 
incidence of mTBI, it may increase the severity of or delay recovery 
from mTBI, at least in adults.198 However, most researchers believe 
additional research is needed before the Apo ϵ4 allele can be used as 
a biomarker of concussion susceptibility.199
For CTE, a study of sixty-eight CTE cases noted that CTE 
occurred with no greater frequency in APOE ϵ4 carriers compared to 
the normal U.S. population.200 In contrast, another review of CTE 
injuries found that in the ten cases of CTE where the APOE 
genotype was reported, five individuals carried at least one APO ϵ4 
allele.201 Other studies have found that older football players who 
carry the APOE ϵ4 allele scored lower on cognitive tests than 
similarly aged players without the allele or less experienced players 
                                                     
195. Eva Brichtová & Libor Kozák, Apolipoprotein E Genotype and 
Traumatic Brain Injury in Children—Association with Neurological Outcome, 24 
CHILD’S NERVOUS SYS. 349, 355 (2008).
196. Terrell et al., supra note 193, at 14; Vicki L. Kristman et al., Does the 
Apolipoprotein ϵ4 Allele Predispose Varsity Athletes to Concussion? A Prospective 
Cohort Study, 18 CLINICAL J. SPORT MED. 322, 327 (2008).  
197. Sam Gandy & Steven T. DeKosky, APOE ε4 Status and Traumatic 
Brain Injury on the Gridiron or the Battlefield, 4 SCI. TRANSLATIONAL MED. 1, 1 
(2012) (finding, through informal poll, that two-thirds of TBI experts are opposed to 
using APOE status at this time to screen for participation in high school or college 
sports).
198. David W. Lawrence et al., The Role of Apolipoprotein E Epsilon (ε)-4
Allele on Outcome Following Traumatic Brain Injury: A Systematic Review, 29 
BRAIN INJ. 1018, 1027 (2015); Lisa M. Moran et al., Apolipoprotein E4 as a 
Predictor of Outcomes in Pediatric Mild Traumatic Brain Injury, 26 J.
NEUROTRAUMA 1489, 1490 (2009). 
199. Michael Makdissi et al., Revisting the Modifers: How Should the 
Evaluation and Management of Acute Concussions Differ in Specific Groups?, 47 
BRIT. J. SPORTS MED. 314, 317-18 (2013); Jeffrey S. Kutcher & James T. Eckner, 
At-Risk Populations in Sports-Related Concussion, 9 CURRENT SPORTS MED. REP.
16, 18 (2010).  
200. Mez, Stern & McKee, supra note 180, at 416. The study found, 
however, that those who were ϵ4 homozygotes were overrepresented compared to 
the U.S. population. Id. Because the study’s results were ambiguous, the researchers 
concluded that further research is needed to determine whether there is a link 
between the ϵ4 allele and CTE. Id.  
201. Ann C. McKee et al., Chronic Traumatic Encephalopathy in Athletes: 
Progressive Tauopathy After Repetitive Head Injury, 68 J. NEUROPATHOLOGY 
EXPERIMENTAL NEUROLOGY 709, 732 (2009). 
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of any genotype, suggesting that the combination of APOE ϵ4 and 
repeated impacts may contribute to long-term cognitive effects.202
These results indicate that the ϵ4 allele may be a genetic risk factor 
for CTE,203 but more studies are needed to determine whether the ϵ4 
allele is actually a genetic risk factor in CTE.  
A more promising genetic marker for mTBI susceptibility may 
be the rare type APOE promoter allele G-219T. The G-219T 
promoter allele (specifically the T/T genotype) is associated with 
lower transcriptional activity (the first step of gene expression in 
which a segment of DNA is copied onto RNA), reducing the amount 
of Apo E expressed.204 In a 2008 study, scientists took genetic 
samples from student–athletes and sequenced their genomes.205 The 
authors found that the presence of the T/T genotype resulted in a 
three-fold higher risk of concussion compared to the normal G/G 
genotype.206 Authors of another study found further evidence of the T 
allele’s genetic susceptibility.207 They surveyed 196 college athletes, 
taking saliva samples to determine their APOE genotype, and found 
that individuals with the rare T allele have more than eight times 
greater chance of concussion.208
The search to identify biomarkers is diverse, widespread, and 
advancing rapidly. Scientists are testing different serum-based 
markers to give us new tools to understanding whether an 
individual’s brain has been injured, how extensive the injury is, 
whether it has been resolved, and whether certain people are more 
susceptible to suffering concussions and CTE. Identifying and 
measuring the presence of biomarkers such as the T-tau protein or 
                                                     
202. Kenneth C. Kutner et al., Lower Cognitive Performance of Older 
Football Players Possessing Apolipoprotein E ϵ4, 47 NEUROSURGERY 651, 655 
(2000). 
203. Id. at 655-56. 
204. Ryan T. Tierney et al., Apolipoprotein E Genotype and Concussion in 
College Athletes, 20 CLINICAL J. SPORTS MED. 464, 466 (2010). The G-219T allele 
alters transcription, changing the amount of Apo E expressed, which may influence 
concussion susceptibility in some cases. Id. at 466-67.
205. Terrell et al., supra note 193, at 11.  
206. Id. at 13. The authors also found those with the G/T genotype did not 
have a statistically higher risk of concussion compared to the G/G normal genotype. 
Id.  
207. Tierney et al., supra note 204, at 466.  
208. Id. at 465-66. Those with the rare promoter allele, and the two rare 
APOE alleles (ϵ2, and ϵ4) were found to be at a ten times higher risk factor. Id. at 
464, 466. This suggests that the rare-type allele in the promoter region may be a 
better indicator of concussive susceptibility than just the ϵ4 allele alone, but the ϵ4 
allele may still be a significant genetic factor in concussive susceptibility.  
1944 Michigan State Law Review  2015:1911 
the APOE gene look particularly promising. Use of these biomarkers 
will undoubtedly begin to seep into the legal landscape and change 
how we evaluate risk and responsibility in law.  
II. TRANSFORMING THE LEGAL LANDSCAPE
The development of reliable biomarkers of effect and 
susceptibility will significantly inform courts and policy makers as 
they wrestle with the complex questions regarding the nature of 
concussive injury, the need for regulation in the area, and the 
allocation of fault and duties with regard to head injuries. In the 
litigation context, biomarker evidence will be judged against 
admissibility standards as embedded in the Daubert principles.209
These admissibility tests may be difficult to meet, but even so, they 
may delay but ultimately not forestall the effect of biomarkers 
seeping into the legal landscape. And as biomarker evidence enters 
the courtroom, the consequences for tort analysis are likely to be 
dramatic. 
A. Legal Implications of Biomarkers of Effect 
The ability to detect biomarkers of effect of concussive injury 
long before clinical symptoms appear may have an impact on each 
element of tort liability. As every first year law student knows, the 
required elements for recovery of damages in tort are: (1) duty; (2) 
breach of duty; (3) causation; and (4) damages.210 Although the 
development of biomarkers will affect these elements in torts 
involving acquired head injury in all settings,211 this Article focuses 
these issues in the context of torts involving youth sports and 
                                                     
209. See Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579 (1993). The 
tests include whether the technique can be tested, whether it has been subjected to 
peer review and publication, whether the potential or known error rate of the 
technique has been determined, and whether the technique has gained general 
acceptance within the scientific community. Id. at 593-94.  
210. DAN B. DOBBS, THE LAW OF TORTS 270-73 (2000).  
211. See, e.g., N.J. Div. of Youth and Family Servs. v. L.G.C., 2010 WL 
1426879 (N.J. Super. Ct. App. Div. 2010) (domestic relations); Garrison v. Shineski, 
No. 10-3614, 2011 WL 6005212 (Vet. App. 2011); Maselter v. Astrue, No. 07-2921 
(RHK/JSM), 2008 WL 4527828 (D. Minn. 2008) (social security disability 
benefits); Weeks Marine, Inc. v. Am. S.S. Owners Mut. Prot. & Indem. Ass’n, No. 
08 Civ. 9878(NRB), 2011 WL 3796331 (S.D.N.Y. 2011) (whether insurance 
coverage for “brain injury” of employees includes concussion); U.S. v. Reilly, 662 
F.3d 754 (6th Cir. 2011) (sentencing variance for veteran).  
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concussive injury.212 Sports present unique challenges in torts 
because the sanctioned athletic activity (such as tackling in football 
or body checking in hockey) would be considered tortious conduct 
under other circumstances. In addition, state legislative action has 
modified standards of care and legal duties in the school sports area.  
1. Duty and Breach 
Duty in the youth-sports area stems from the general common 
law obligation to provide a relatively safe environment to engage in 
the activity.213 Concussive management on the playing field is the 
first area of concern. This may include the duty of sports sponsors to 
inform players about the risks of concussions, provide equipment, 
implement both rules and a playing environment that do not impose 
unreasonable risks of injury, accurately diagnose concussions, and 
remove players from play and not to allow them to return until their 
concussions have resolved.  
Legal duties for concussive injury prevention and management 
trace to a mixture of legislation and common law principles. This 
Subsection examines both, including examination of return-to-play 
legislation under state law, as well as the rise of the use of athletic 
trainers as the front line for concussive management. These 
approaches to concussion management only address management of 
“acute” concussion and do not address the long-term issues 
associated with concussion,214 except in a general sense.  
Significant challenges exist to concussive management. 
Concussive management depends on the cooperation of the player 
and candor in reporting symptoms.215 Some players simply may not 
                                                     
212. It is generally accepted that two populations are at a heightened risk for 
concussion and mTBI: athletes and military combat personnel. L. Syd M. Johnson, 
Brad Partridge & Frédéric Gilbert, Framing the Debate: Concussion and Mild 
Traumatic Brain Injury, 8 NEUROETHICS 1, 2 (2015) [hereinafter Johnson, Framing 
the Debate]. This Article focuses on legal duties for concussive management with 
regard to athletes. Legal duties involved in combat personnel are dominated by 
sovereign immunity issues. Jonathan Turley, Pax Militaris: The Feres Doctrine and 
the Retention of Sovereign Immunity in the Military System of Governance, 71 GEO.
WASH. L. REV. 1, 1-2 (2003). Furthermore, diagnosis and treatment of mTBI for 
combat victims are complicated by the similarity of symptoms with PTSD. Johnson, 
Framing the Debate, supra. 
213. See, e.g., Searles v. Trs. of Saint Joseph’s Coll., 695 A.2d 1206, 1209 
(Me. 1997). 
214. Long-term issues will be discussed infra at Subsection II.A.2.  
215. Johnson, supra note 41, at 19. 
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recognize the symptoms of a concussion.216 In addition, there are 
powerful, coercive social and economic pressures to underreport 
symptoms.217 The resistance to reporting concussion symptoms exists 
at all levels of sports,218 including high school.219
A further challenge to concussive management is the lack of 
consensus regarding the definition, diagnosis, and treatment for 
concussions.220 The current approach generally only addresses 
clinically evident concussions.221
a. Return-to-Play Determinations Under State Law 
States have been at the forefront in regulating concussive injury 
in the youth-sports area.222 All fifty states and the District of 
Columbia now have legislation to prevent concussions and to limit 
further injury to student–athletes who sustain concussions.223 States 
                                                     
216. Andrew W. Breck, Note, Keeping Your Head on Straight: Protecting 
Indiana Youth Athletes from Traumatic Brain Injuries Through “Return-to-Play” 
Legislation, 9 IND. HEALTH L. REV. 215, 221 (2012). 
217. Johnson, supra note 41, at 20. 
218. John Keim, Most Would Play SB with Concussion, ESPN (Jan. 28, 
2014), http://espn.go.com/nfl/story/_/id/10358874/majority-nfl-players-play-super-
bowl-concussion-espn-survey (reporting that 85% of players surveyed would play in 
the Super Bowl with a concussion); NFL Concussion Poll: 56 Percent of Players 
Would Hide Symptoms to Stay on Field, SPORTING NEWS (Nov. 12, 2012), http:// 
www.sportingnews.com/nfl/story/2012-11-11/nfl-concussions-hide-symptoms-
sporting-news-midseason-players-poll (reporting that 56% of NFL players surveyed 
would try to hide concussion symptoms).  
219. Johnson, supra note 41, at 19; see also Frederick P. Rivara et al., The 
Effect of Coach Education on Reporting of Concussions Among High School 
Athletes After Passage of a Concussion Law, 42 AM. J. SPORTS MED. 1197, 1197 
(2014) (discussing a study of Washington State, the first state to adopt return-to-play 
legislation, which found that over two-thirds of high school athletes who suffered 
mTBI reported playing with symptoms); Emily Kroshus et al., Concussion Under-
Reporting and Pressure from Coaches, Teammates, Fans and Parents, 134 SOC.
SCI. & MED. 66, 66 (2015) (quantifying, in study of 328 players at four colleges in 
seven sports, the pressure from coaches, teammates, parents, and fans to continue to 
play after head impact). 
220. Johnson, Partridge & Gilbert, supra note 212, at 2. 
221. Johnson, supra note 41, at 15-16.  
222. Various concussion management protocols have also been voluntarily 
adopted by sports teams and leagues. Critics argue that these protocols are vague, 
“wide open to interpretation by trainers and medical staffs,” and not empirically 
validated. Johnson, supra note 41, at 19. 
223. See CTRS. FOR DISEASE CONTROL, GET A HEADS UP ON CONCUSSION IN 
SPORTS POLICIES INFORMATION FOR PARENTS, COACHES, AND SCHOOL & SPORTS 
PROFESSIONALS 1, 4 (n.d.), http://www.cdc.gov/headsup/pdfs/policy/ 
headsuponconcussioninsportspolicies-a.pdf  
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have dominated legislative action in this area, since there is no 
federal law that regulates youth athletic concussions, nor is there a 
central governing body to promulgate health and safety standards.  
The goal of return-to-play legislation is to ensure that student–
athletes recover from concussions and do not play with an injured 
brain.224 The legislation is generally focused on managing single 
instances of concussion and is based on the assumption that 
preventing concussed players from returning to play before their 
symptoms have resolved will lower the risk of developing long-term 
cognitive impairment.225 Most state statutes have three major 
components: (1) removal from play, (2) medical clearance for return 
to play, and (3) education. Generally, the statutes charge the school 
districts, the state department of health or board of education, or the 
athletic association to implement the statutes.226 Although these 
statutes have much in common, their most noteworthy characteristic 
is their lack of uniformity.  
The vast majority of these laws mandate that student–athletes 
who experience a concussion be removed from play and obtain a 
specified individual’s permission before returning to play.227 The 
statutes vary on who can grant that permission, although most 
statutes require a health care provider trained in the evaluation and 
management of concussions to make the determination.228 States 
differ on whether the health care provider is required to be “licensed” 
or a neutral decision maker.229 In other words, some states allow 
                                                     
224. Breck, supra note 216, at 218. 
225. See Steven P. Broglio et al., National Athletic Trainers’ Association 
Position Statement: Management of Sport Concussion, 49 J. ATHLETIC TRAINING
245, 249-51 (2014). 
226. See, e.g., N.M. STAT. ANN. § 22-13-31(D) (West 2015) (charging school 
districts with development and implementation responsibilities); OKLA. STAT. ANN.
tit. 70, § 24-155(A) (West 2015) (charging school districts and athletic associations 
with implementation responsibilities). 
227. CHILDREN’S SAFETY NETWORK, LEGISLATION ON SPORTS-RELATED 
CONCUSSIONS 1 (Sept. 2013), http://www.childrenssafetynetwork.org/sites/ 
childrenssafetynetwork.org/files/CSN_SportsConcussion_Legislation2013.pdf. 
Wyoming does not specifically require medical evaluation or clearance before a 
youth athlete is permitted to return to play. See WYO. STAT. ANN. § 21-3-110 (West 
2015).  
228. Some states allow medical clearance by any health care provider. See, 
e.g., ARIZ. REV. STAT. § 15-341(24)(b) (2015).  
229. For example, Arizona’s definition of a health care provider includes 
physicians, athletic trainers, nurse practitioners, and physician’s assistants who have 
been trained in the evaluation and management of concussions and head injuries. 
See § 15-341(24)(b). Alabama and Texas require a licensed physician to make the 
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anyone who has been trained to be an evaluator, and even a coach 
may suffice.230
Although most states require training in head injuries, the states 
vary on who is responsible for developing the training protocols and 
who is required to receive the training.231 The majority of states 
simply delegate education initiatives to the state’s school districts 
with no further instruction.232 Although most of the statutes require 
distribution of information to coaches and students regarding 
concussions, only some of them require in-depth training for
coaches.233 Many states do not require students to complete training, 
even though diagnosis currently depends heavily on the player 
recognizing internal symptoms.234
Most states do not mandate a waiting period before returning to 
play.235 Only a few states require the schools to collect concussion 
data, and significantly, not a single statute requires baseline testing 
of student–athletes before the season.236
                                                                                                               
return-to-play determination. ALA. CODE § 22-11E-2(d) (2015); TEX. EDUC. CODE 
ANN. § 38.157(a)(1) (West 2015). California requires a licensed health care 
provider, meaning a health care provider who is trained in the management of 
concussion. CAL. EDUC. CODE § 49475 (West 2015).  
230. A few states do not address who will make the determination. See, e.g.,
2011 ILL. LAWS 97-0078.  
231. Many states do not require the participation of a medical or public 
health entity in the development of their education initiatives. See, e.g., IDAHO CODE 
ANN. § 33-1625(1) (West 2015); N.J. STAT. ANN. § 18A:40-41.3(b) (West 2015). 
232. See, e.g., COLO. REV. STAT. ANN. § 25-43-103(1)(a) (West 2015) 
(charging each public school with responsibility of educating coaches annually 
regarding concussions); TENN. CODE ANN. § 68-55-502(b)(1)(A)-(B) (West 2015) 
(stating that public schools should create guidelines regarding treatment of 
concussions and that coaches should be trained annually on that treatment). 
233. See, e.g., OR. REV. STAT. ANN. § 336.485(2)(a) (West 2015). Those 
states that require training vary on how often training should take place. See Kevin 
Brandwein, Goals and Obstacles in Legislating Concussion Management in Youth 
Sports, 10 WILLAMETTE SPORTS L.J. 28, 46 (2013). 
234. Most of the statutes require distribution of information to parents, and 
most—but not all—of the statutes require students and parents to sign a form 
confirming the receipt of concussion information. Brandwein, supra note 233, at 46; 
see, e.g., WIS. STAT. ANN. § 118.293(3)(a) (West 2015) (requiring only a parent’s 
signature prior to preseason under Wisconsin law). 
235. California has the longest (seven day) mandatory waiting period. CAL.
EDUC. CODE § 49475(a)(1) (West 2015). In contrast, Arizona allows a student to 
return to play the next day if the trained health care provider clears the player. ARIZ.
REV. STAT. § 15-341(24)(b) (2015). 
236. See Hosea H. Harvey, Reducing Traumatic Brain Injuries in Youth 
Sports: Youth Sports Traumatic Brain Injury State Laws, January 2009–December 
2012, 103 AM. J. PUB. HEALTH 1249, 1249-54 (2013).  
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This diversity of approaches reflects the lack of consensus on 
the best approach to concussive management.237 Some commentators 
question the efficacy of these types of concussive management 
legislation altogether, especially when the risks and mechanics of 
mTBI injuries are not fully understood.238 Furthermore, current laws 
and regulations do not specify how to determine the presence of a 
concussion, leaving it to the discretion of the evaluator, who may or 
may not be a licensed health care provider.  
Development of biomarkers of effect will reshape this 
legislative landscape. It will lead the way toward establishing 
evidence-based guidelines for making return-to-play decisions after 
concussions and in reducing the problems created by the dependence 
on self-reporting by the player. As use of biomarkers becomes 
standard medical procedure, regulatory bodies are likely to 
incorporate these tests into their requirements, which should lead to 
greater standardization, particularly in the requirements for removal 
from play, medical clearance, and education. Legislation or 
regulations may specify the use of biomarkers for the return-to-play 
determination, as well as require evaluators who are trained in the 
use of biomarkers and qualified to interpret them. Furthermore, 
statutes may require the creation of baselines for each athlete, once a 
biomarker gives us something to measure.239 In this way, when there 
is evidence of a potential concussion, trained personnel can compare 
the levels of the biomarkers post-injury to those baseline 
measurements.240
                                                     
237. Johnson, supra note 41, at 24 (“To be effectively neuroprotective . . . it 
is likely RTP protocols would have to be significantly more conservative and 
restrictive, and require a much longer period of rest and recovery.”).
238. See Johnson, Partridge & Gilbert, supra note 212, at 2-3. Critics point 
out that the statutes do not require changes to how the sport itself is played. Johnson, 
supra note 41, at 24. 
239. Some leagues have begun to use neuropsychological testing to create 
baselines. Christopher Randolph, Baseline Neuropsychological Testing in Managing 
Sport-Related Concussion: Does It Modify Risk?, 10 CURRENT SPORTS MED. REP. 
21, 21 (2011). These are subject to “sandbagging,” or intentional manipulation by 
the players, to avoid later detection of concussions. For example, Peyton Manning 
admitted to deliberately sandbagging the baseline test. See Rick Reilly, Talking 
Football with Archie, Peyton, Eli, ESPN (Apr. 27, 2011, 9:32 AM), 
http://sports.espn.go.com/espn/news/story?id=6430211.  
240. As mentioned above, no statute currently requires baseline testing of 
student–athletes. Some athletic programs have adopted a form of baseline testing 
through cognitive testing programs. Some programs, such as imPACT, implement 
baseline testing, but this test is adopted solely on a voluntary basis. See About 
ImPACT, IMPACT, https://www.impacttest.com/about/ (last visited Feb. 13, 2016). 
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Similarly, collection of concussion data, both pre- and post-
season, will likely become standard through legislation, regulation, 
or protocol. The data will allow schools and sports leagues to 
identify individual, at-risk players as well as to discern overall group 
patterns that may have an impact on policies on concussive 
management, such as how long a waiting period appears most 
effective. The availability of such data will help shape future public 
health measures as well.  
At the same time, the development and validation of 
biomarkers will create their own set of new complexities and 
questions. With so many different types of biomarkers in different 
stages of development, there will be issues as to which biomarkers 
should be used and when. It is likely that there will be frequent 
changes in best practices with regard to the choice and application of 
biomarkers as the science in this area rapidly changes. Who should 
specify which biomarkers are the state of the art and should be used? 
If it is the legislature, there may be problems keeping the statutes up 
to date with constantly shifting science. If that responsibility is 
delegated, there may be problems with consistency and 
accountability. Another set of issues is how much reliance should be 
placed on rapid, real-time “on the sidelines” biomarker assays, such 
as a blood screen, versus more expensive and rigorous tests—
involving brain scans or other technologies—that can only be 
conducted away from the playing field. 
On a broader scale, with the identification of biomarkers, there 
may be more calls for uniform federal legislation, regulations, or 
creation of a uniform model code for the states to follow. This 
alignment could lead to a minimum standard of concussion 
prevention, care, and management and could incorporate—either 
directly or indirectly—the use of biomarkers. Standardization would 
likely include requiring baseline testing at the beginning of each 
season and requiring schools and teams to report concussion 
incidents to a registry. Such legislation could potentially include civil 
liability or penalties for noncompliance.  
b. Private Law Remedies 
Individuals will continue to seek private law remedies against 
the sponsors of sports activities and those involved in managing 
players. These claims will be made in professional malpractice 
lawsuits or in negligence claims against the entity sponsoring the 
athletic event.  
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The standard of care is typically determined by the conduct of a 
reasonable person of ordinary abilities under the same circumstances, 
but this duty is generally enhanced when the defendant possesses 
special knowledge, skill, training, or experience that is superior to 
the ordinary person.241 Accordingly, coaches, trainers, and other 
professionals may be held to this higher standard of care. Practicality 
and costs of using biomarkers will enter into the equation of whether 
a given duty exists and whether the failure to use them might 
constitute the breach of duty to provide a safe environment.242 An 
important dynamic in addressing these questions is: “What are other 
teams and leagues doing?” Thus, if one or two college-based or high 
school teams start baseline biomarker testing of their players, will 
that set a standard of care that may create liability risks for similar 
teams or leagues? Will this potential to create new standards of 
liability act as a deterrent to prevent teams or leagues from adopting 
new biomarker tests and baseline testing?  
The duty and breach issues that could arise in these lawsuits 
include the failure to create a baseline, the failure to timely screen for 
a concussion, the misdiagnosis of a concussion, and the misdiagnosis 
of treatment and cessation of a concussion, including allowing a 
student athlete to return to play with the continued presence of 
concussion biomarkers. These claims may arise even if the state 
statute does not address these issues; but if the legislation does 
address them, plaintiffs will argue that the statute creates a minimum 
standard of care. Some of these claims are discussed below in the 
context of athletic trainers, whose use is on the rise.243
Athletic trainers are certified health care professionals who 
work closely with physicians to “provide preventative services, 
                                                     
241. DOBBS, supra note 210, at 288-90; see Cerny v. Cedar Bluffs 
Junior/Senior Pub. Sch., 628 N.W.2d 697, 706 (Neb. 2001) (finding the standard of 
care regarding diagnosis of concussive injury owed by members of coaching staff to 
be that of a reasonably prudent person holding a state teaching certificate with 
coaching endorsement; dismissing complaint seeking to recover injuries allegedly 
resulting from negligence of coaches who allowed concussed player to reenter 
game). 
242. See United States v. Carroll Towing Co., 159 F.2d 169, 173 (2d Cir. 
1947) (discussing the “Learned Hand formula” of duty; balancing the magnitude of 
the loss if an accident occurs, the probability of the accident’s occurring, and the 
burden of taking precautions that would avoid it). 
243. Colin Poitras, Pressing Need for Full-Time Athletic Trainers in High 
Schools, UCONN TODAY (Mar. 27, 2015), http://today.uconn.edu/2015/03/pressing-
need-for-full-time-athletic-trainers-in-high-schools (reporting that the use of athletic 
trainers has doubled in the last two decades and that about 70% of public high 
schools have athletic trainers).  
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emergency care, clinical diagnosis, therapeutic intervention and 
rehabilitation of injuries and medical conditions.”244 Generally, 
athletic trainers work continuously with players and usually are the 
first-responding health care providers when injury strikes.245 As first 
responders on the playing field, the diagnosis and treatment of 
concussions are often solely shouldered by athletic trainers. The 
exact responsibilities given to athletic trainers, however, vary 
depending on the state, school, and skill levels of the trainers. 
Athletic trainers are often given specialized duties with regard 
to concussive injury management.246 Trainers initially diagnose 
concussions, evaluate the player and determine when it is safe to 
return to play, and oversee the rehabilitation and treatment of the 
concussion.247 While trainers are encouraged to send the injured 
athlete to a physician, they often manage the injury themselves.248
The largest accrediting organization, the National Athletic Trainer’s 
Association (NATA), provides continuing education, which can 
include concussive injury management.249
                                                     
244. Athletic Training, NAT’L ATHLETIC TRAINERS’ ASS’N,
http://www.nata.org/athletic-training (last visited Feb. 13, 2016). Athletic trainers 
work under various job titles such as occupational health manager, physician 
extender, or rehabilitation specialist. Id. To become an athletic trainer, students must 
complete a collegiate academic major and then be certified by the national 
organization, National Athletic Trainer’s Association (NATA). Id. The Commission 
on Accreditation of Athletic Training Education accredits the college program. 
Students who finish their baccalaureate degree then must pass the NATA Board of 
Certification (BOC) examination to be nationally certified. NAT’L ATHLETIC 
TRAINERS’ ASS’N, ATHLETIC TRAINING EDUCATION OVERVIEW 1, http://www. 
nata.org/sites/default/files/AT-EducationOverview.pdf (last visited Feb. 13, 2016). 
Forty-seven states require this certification to practice athletic training. Id. at 2.  
245. Schools, training facilities, clinics, physicians’ offices, and sporting 
venues employ athletic trainers to help athletes condition and perform. Athletic 
Training, supra note 244. At the secondary school level, schools generally hire the 
trainers as independent contractors. Id.  
246. Alexandra Svokos, A Majority of High Schools Lack Full-Time Athletic 
Trainers to Keep Kids Safe, HUFFINGTON POST (Nov. 18, 2014, 6:29 AM), http:// 
www.huffingtonpost.com/2014/11/18/high-school-athletic-trainers_n_6146672.html.  
247. Broglio et al., supra note 225, at 245. 
248. Id.
249. See, e.g., Concussion Wise for Athletic Trainers, CONCUSSIONWISE,
http://www.concussionwise.com/concussion-wise-athletic-trainers (last visited Feb. 
13, 2016). However, continuing education units are not specified. See Certification 
Maintenance Requirements, BOARD CERTIFICATION FOR ATHLETIC TRAINER,
http://www.bocatc.org/ats/maintain-certification/continuing-education (last visited 
Feb. 13, 2016) (listing available units). 
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Some states specify the use of athletic trainers as qualified 
health care professionals under return-to-play legislation,250 but many 
schools, especially at the high school level, do not hire them due to 
lack of funding, small school size, rural location, or a belief that 
coaches will suffice.251 Despite the inevitable risks of not having a 
physician present throughout the stages of a concussive injury, some 
studies suggest that use of athletic trainers helps student–athletes 
more than it hurts them.252 The studies indicate that high schools that 
employ athletic trainers have lower overall injury rates, and 
concussions are more likely to be properly diagnosed.253
At the same time, the effectiveness of using athletic trainers in 
concussive management may be undermined by conflict-of-interest 
pressures. In an informal 2013 survey of athletic trainers working for 
college football programs, nearly half of the trainers responded that 
they have felt pressure from the coaches to return the injured player 
to play before the players were medically approved to do so.254 This 
problem is exacerbated by the fact that athletes, who also feel 
pressure to return to play, may misreport their symptoms to the 
trainer.255
Trainers may be subject to tort liability for failing to adhere to 
recognized practices for concussive management.256 Determining the 
                                                     
250. See, e.g., ARIZ. REV. STAT. ANN. § 15-341(24)(b) (2015). 
251. Svokos, supra note 246. 
252. Press Release, Am. Acad. Pediatrics, High Schools with Athletic 
Trainers Have More Diagnosed Concussions, Fewer Overall Injuries (Oct. 22, 
2012), https://www.aap.org/en-us/about-the-aap/aap-press-room/pages/High-Schools- 
with-Athletic-Trainers-have-More-Diagnosed-Concussions-Fewer-Overall-Injuries.aspx. 
253. Id.  
254. Brad Wolverton, Coach Makes the Call: Athletic Trainers Who Butt 
Heads with Coaches over Concussion Treatment Take Career Hits, CHRON. HIGHER 
EDUC. (Sept. 2, 2013), http://chronicle.com/article/Trainers-Butt-Heads-With/141333.
Of the 101 trainers surveyed, thirty-two reported that the coaching staff had hiring 
and firing power over their position, fifty-three reported they felt pressure to return a 
student to play faster than they feel they should have, and forty-two said they felt 
pressure to return a student to the field even after he experienced a concussion. Jerry 
Hinnen, Survey: 42 Percent of Trainers Pressured to OK Concussed Players, CBS
SPORTS (Sept. 4, 2013, 1:28 PM), http://www.cbssports.com/collegefootball/eye-on-
college-football/23476122/survey-42-percent-of-trainers-pressured-to-ok-concussed-
players. 
255. Id.; see supra note 213-19 and accompanying text.  
256. Barbara Osborne, Principles of Liability for Athletic Trainers: 
Managing Sport-Related Concussion, 36 J. ATHLETIC TRAINING 316, 316, 318-19
(2001). But see Morris v. Adm’rs of Tulane Ed. Fund, 891 So.2d 57, 61 (La. Ct. 
App. 2004) (holding that athletic trainers are not “health care providers” under the 
state medical malpractice act and thus do not automatically qualify for protection 
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legal standard of care is difficult, however, if there is no universally 
accepted standard for concussion diagnosis and treatment by athletic 
trainers.257 While courts generally take into account NATA’s 
guidelines, these guidelines are not determinative.258 Courts have 
already recognized that athletic trainers owe players a duty of care in 
concussive management.259 For example, the plaintiff in Pinson v. 
State260 suffered a blow to the head during football practice, walked 
to the sideline, and then collapsed unconscious.261
The school’s athletic trainer sent him in an ambulance to the 
hospital262 but failed to properly inform the physician of Pinson’s 
symptoms and the time he lost consciousness.263 After his release, 
Pinson repeatedly complained of headaches and nausea to the trainer, 
but the trainer nonetheless cleared him to return to play.264 When he 
collapsed at another practice, Pinson remained in a coma for several 
weeks and suffered severe, permanent neurological damage.265 After 
Pinson brought suit, the court held that the athletic trainer did not 
exercise the required standard of care and breached his duty when he 
failed to report Pinson’s headaches to the physician.266 The court 
found that the athletic trainer was responsible for 30% of the 
plaintiff’s damages.267
As the use of athletic trainers continues to rise, the duty of care 
imposed on them almost certainly will encompass biomarker testing 
                                                                                                               
under the statute). Trainers may keep professional liability insurance. See, e.g.,
Athletic Trainers, PROLIABILITY, http://www.proliability.com/professional-liability-
insurance/athletic-trainers (last visited Feb. 13, 2016).  
257. Osborne, supra note 256, at 317. 
258. Marie-France Wilson, Young Athletes at Risk: Preventing and 
Managing Consequences of Sports Concussions in Young Athletes and the Related 
Legal Issues, 21 MARQ. SPORTS L. REV. 241, 281-82 (2010). 
259. If a team does not have a medical trainer, the coach will likely be 
identified as the responsible party and be subject to potential liability. The absence 
of an athletic trainer could be a source of culpability for the team or league if the 
judge or jury finds that the standard of care requires a properly trained athletic 
trainer to be on the sidelines. 
260. Pinson v. State, No. 02A01-9409-BC-00210, 1995 WL 739820, at *4 
(Tenn. Ct. App. 1995).  
261. Id. at *1. 
262. Id. The athletic trainer found palsy on the left side of Pinson’s face, 
noting that he had no control of the left side of his body and no response to pain, 
sound, or movement. Id.  
263. Id.  
264. Id. at *1-2.
265. Id. at *2. 
266. Id. at *7. 
267. Id. at *3.  
 Biomarkers, Concussions, and the Duty of Care 1955 
once it can be practically employed on or near the playing field. 
Availability of such tests will encourage schools to employ athletic 
trainers to administer them. NATA may require training and use of 
the biomarkers in concussive management, but regardless, the tests’ 
availability will raise and perhaps clarify the professional standard of 
care of athletic trainers.268 The availability of objective measures may 
also serve to protect athletic trainers from liability, since they 
currently rely mostly on subjective measures. Moreover, the use of 
such tests will make it easier for trainers to consistently adhere to 
proper procedures, as well as enhance their ability to resist conflict-
of-interest pressures. At the same time, increasing the exposure to 
liability for concussive management may have the unintended 
consequence of discouraging organized sports in schools.  
c. Duty to Screen and Monitor 
The availability of biomarkers of effect may expand the 
concussive management duties of schools or other sponsors of youth 
sports teams to include periodic testing of their players for biomarker 
indications of concussive injury. These duties may include testing 
players before play, during the season, and after the season. Pre-play 
screening will establish an individual player’s baseline, while 
monitoring will help determine whether the player has suffered 
concussive injury and whether the concussion is resolved, making it 
safe to return to play. This duty may arise even if a player does not 
manifest outward symptoms of brain injury.  
Pre-season and periodic screening for mTBI with biomarkers 
will pose many challenges. The high incidence of concussive 
injury269 may engender a greater duty to screen and monitor youth 
athletes. However, what constitutes this duty may change based on 
the type of testing available. The cost of a serum assay (to determine 
the amount of a particular biomarker in blood) is estimated to be 
                                                     
268. Again, the issue of which biomarkers are the current state of the art will 
complicate decisions on which biomarkers to use and the relevant standard of care.  
269. For example, the rate of concussive injury in NCAA football was 
3.1/1,000 athletic exposures in the 2004 to 2009 season. NCAA, GUIDELINE 2I:
CONCUSSION OR MILD TRAUMATIC BRAIN INJURY (MTBI) IN THE ATHLETE 1 (2010), 
http://www.muhlenberg.edu/pdf/main/athletics/athletic_training/2010-
11ncaaconcussions_mtbi.pdf. An athletic exposure includes both games and 
practices. Although the statistics between SCD and concussion incident rate are not 
the same measure, it is readily apparent that concussive injury is much more 
frequent. 
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around $20 to $25.270 Although this cost is not large on an individual 
basis, it may become a large burden with widespread 
implementation. Regardless, this cost is much lower than the cost of 
a CT or MRI scan.271 Additionally, the cost also depends on when the 
duty to screen arises—only pre-season, regularly throughout the 
season, or only after injury. While there is clearly a duty for teams to 
check their athletes for injury as part of their reasonable duty of 
care,272 the extent of this duty is undetermined.273 What particular 
advantage or benefit would screening athletes prior to a season and 
during a season provide?274 Should all athletes be screened, and how 
                                                     
270. The cost of a S100B assay was estimated to be from $15 to $25. 
Shuolun Ruan, Katia Noyes & Jeffrey J. Bazarian, The Economic Impact of S-100B 
as a Pre-Head CT Screening Test on Emergency Department Management of Adult 
Patients with Mild Traumatic Brain Injury, 26 J. NEUROTRAUMA 1655, 1658 (2009).  
271. See id. Outside of a biomarker assay, an athletic association could also 
submit a questionnaire to athletes regarding previous concussive injury and current 
symptoms and also evaluate them using the Glasgow Coma Score throughout and 
before the season. These questionnaires and self-reporting methods would be low-
cost, but are less objective than a biomarker assay or imaging scan, as they rely on 
self-reporting symptoms as opposed to an objective measure.  
272. See Searles v. Trs. of Saint Joseph’s Coll., 695 A.2d 1206, 1209 (Me. 
1997) (holding that coaches and athletic trainers have a duty to exercise reasonable 
care for the health and safety of athletes that may include monitoring a knee injury 
during the season and overturning defendant’s motion for summary judgment).  
273. For example, would a regular test require only self-reporting symptoms 
and determination of a Glasgow Coma Score, or would it require assays of serum for 
biomarkers or comprehensive imaging tests? Settlement negotiations from a recent 
lawsuit against the NCAA may give insight into how the duty may be analyzed. The 
proposed settlement requires that 
[f]irst, the NCAA will institute a policy requiring all student-athletes 
to undergo pre-season baseline testing for each sport they play prior to 
beginning practice or competition. Second, the NCAA will revise its 
return-to-play guidelines to provide that “[s]tudents with a diagnosed 
concussion will be prohibited from returning to play or participation in 
any practice or game on that same day and must be cleared by a physician 
before being permitted to return to play in practice or competition.” Third, 
medical personnel, who are trained in the diagnosis, treatment, and 
management of concussions, will be present at all games of Contact 
Sports—defined as football, lacrosse, wrestling, ice hockey, field hockey, 
soccer, and basketball—and be available during all Contact Sports 
practices.  
In re NCAA Student-Athlete Concussion Injury Litig., 2014 U.S. Dist. LEXIS 
174334, at *16-17 (N.D. Ill. Dec. 17, 2014) (citations omitted). The proposed 
settlement also requires reporting of a concussion and providing concussion 
education to athletes and faculty. Id. at *18. 
274. Hopefully, injuries would be prevented by tracking down those already 
symptomatic of concussive injury and preventing them from returning to play.  
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often should the screening occur? What is the duty to a student who 
starts late in the season? Questions like these will have to be 
addressed to determine screening and monitoring duties and 
consequent liability risks. Furthermore, this duty may also depend on 
the development of other new devices to detect concussive injury 
and determine severity on the sidelines, potentially used in 
conjunction with biomarkers.275
2. Medical Monitoring and Increased Risk Claims 
Although advances in biomarker research will directly affect 
concussive management duties on the playing field, these advances 
also implicate other, less obvious, concussive management duties. 
Biomarkers will give us a deeper understanding of the disease 
process and trace back earlier into what we think of as the diseased 
state. In this way, successive concussive injuries implicate a potential 
latent risk for CTE, since CTE is a progressive condition associated 
with repetitive brain injury that may take years to develop.  
                                                     
275. Kara E. Schmid & Frank C. Tortella, The Diagnosis of Traumatic Brain 
Injury on the Battlefield, 3 FRONTIERS NEUROLOGY 1, 2 (2012). A variety of tests are 
being developed. Currently, one may take ELISAs (enzyme-linked immunosorbent 
assays) to measure the amount of a biomarker in serum. Id. at 3. An ELISA is a 
laboratory technique in which samples are plated onto a tray, and the concentration 
of a marker in the sample is calculated. See An Introduction to ELISA, ABD
SEROTEC, https://www.abdserotec.com/an-introduction-to-elisa.html (last visited 
Feb. 13, 2016). However, ELISAs can take four to twenty-four hours to complete. 
Schmid & Tortella, supra, at 3. A cartridge for an I-STAT (a handheld blood reader) 
is in development that may detect concussions using UCH-L1 and GFAP 
biomarkers (mentioned above), which are present as soon as fifteen minutes after 
injury. Michele D. Sullivan, Biomarker Test May Allow Immediate Diagnosis of 
Concussion, CLINICAL NEUROLOGY NEWS (Aug. 28, 2014), http://www. 
clinicalneurologynews.com/index.php?id=9868&tx_ttnews%5Btt_news%5D=294465
&cHash=b99dda1fa2164b3a2190d785a83e45f7. Should these devices become 
available to the public, athletic organizations may have a duty to carry them in 
sports competitions to quickly and efficiently determine if concussive injury 
occurred. These devices may be deployed in the military as early as 2016. Id.
However, due to the high cost of an I-STAT, requiring such a device at all games 
and practices may be too burdensome. See I-STAT Portable Clinical Analyzer,
ALLIVET, http://www.allivet.com/p-2452-i-stat-portable-clinical-analyzer.aspx?gclid= 
CjwKEAjwxMetBRDJx6Sz2p7DsQ0SJADJHAqN1mFPG6aQAjRQlKygks4dCaTlL
Po98lSnY2nz2r9PJxoC21Dw_wcB (last visited Feb. 13, 2016). Another portable 
device that may be able to detect concussions is a portable functional near-infrared 
spectroscopy device. Researchers Find Portable, Low-Cost Optical Imaging Tool 
Useful in Concussion Evaluation, SCIENCEDAILY (June 26, 2014), 
http://www.sciencedaily.com/releases/2014/06/140626022036.htm. The device 
accurately indicated concussive injury and would be low cost. Id.  
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Latent injury claims confront the fundamental tort principle 
that the plaintiff must demonstrate “harm” (typically a physical 
harm) before being allowed to recover damages.276 In addition, the 
time gap between exposure and disease creates significant practical 
hurdles in recovery, such as statutes of limitations and proof 
problems from dated evidence. Despite these jurisprudential and 
practical problems, courts have recognized in latent injury toxic tort 
cases a set of compensatory damages during the latency period that 
may exist between exposure and disease.277 These latent injury torts 
reflect the view that certain injuries follow a continuum between an 
initial event, such as exposure, and a medically diagnosable disease.  
Latent injury claims permit a claimant to receive compensation 
before a serious disease has been manifested. Proponents argue that 
the claims promote the public health interest in fostering access to 
medical testing, stressing the value of early diagnosis and treatment 
for many types of diseases.278 Similarly, by mitigating serious future 
illnesses, the claims can reduce the overall costs to the responsible 
parties as well as to society.279 Moreover, the claims can enhance 
deterrence for risk creation.280 Finally, they reflect basic societal 
notions of fairness and elemental justice by allowing the individual 
who has been wrongfully exposed to a likely future injury to receive 
compensation for the fear of getting the future injury, as well as 
avoid bearing the expense of medical monitoring.281 Other supporters 
suggest that, by allowing recovery for the latent risk itself rather than 
waiting for the serious disease manifestation, the claims address 
practical problems such as access to proof.282
Critics argue that latent injury claims are brought by 
individuals who, despite exposure to a hazard, have not yet been 
significantly injured and, therefore, are not yet entitled to 
                                                     
276. See Jamie A. Grodsky, Genomics and Toxic Torts: Dismantling the 
Risk-Injury Divide, 59 STAN. L. REV. 1671, 1673 (2007). 
277. The latent injury claims emerged out of asbestos claims, among others. 
See id. at 1682-83.  
278. Gary E. Marchant, Genetic Susceptibility and Biomarkers in Toxic 
Injury Litigation, 41 JURIMETRICS J. 67, 84 (2000) [hereinafter Marchant, Genetic 
Susceptibility].
279. Anita J. Patel, Medical Monitoring: Missouri’s Welcomed Acceptance,
73 MO. L. REV. 611, 623 (2008). 
280. Marchant, Genetic Susceptibility, supra note 278, at 85. 
281. James Pizzirusso, Increased Risk, Fear of Disease and Medical 
Monitoring: Are Novel Damage Claims Enough to Overcome Causation Difficulties 
in Toxic Torts?, 7 ENVTL. LAW. 183, 202 (2000). 
282. Marchant, Genetic Susceptibility, supra note 278, at 85.  
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compensation.283 They contend that this claim should not be 
recognized too readily for fear of flooding the courts with frivolous 
claims and disproportionately burdening defendants.284 A major 
concern is limited resources, so that if money is allocated now for 
these damages, sufficient money may not be available later for 
recovery by those who actually suffer from the disease in question.285
Three types of claims generally arise in the latent risk area. 
Claimants may seek recovery for: (1) the increased risk of a disease; 
(2) the fear of developing future disease; and (3) medical monitoring 
costs.286 All of these claims are based on the premise that the plaintiff 
has either incurred some injury or has been exposed to a hazard and, 
as a result, is now at an increased risk of future disease. These claims 
all require that the increased risk be significant.287 Aside from these 
commonalities, these are distinctive claims, however. The first, 
increased risk, seeks compensation for the fact of the increased risk 
itself, assigning a value to the increased risk without any certainty 
that the disease will later manifest; the second, fear of future injury, 
is an emotional harm claim for the fear and anxiety of getting the 
more serious disease; and the third, medical monitoring, is seeking 
payment for the cost of monitoring the at-risk, exposed plaintiff to 
detect and prevent the onset of disease.288
Medical monitoring is the most widely used of these claims, 
although no consensus exists regarding the elements of the claim.289
                                                     
283. Id.
284. Id.
285. Id.
286. Marchant, Genetics and Toxic Torts, supra note 113, at 976.  
287. In Donovan v. Philip Morris USA, Inc., the plaintiffs alleged that 
Marlboro cigarette smoke, with excessively high levels of carcinogen, caused 
physiological changes and lung tissue damage that led to significantly increased risk 
of lung cancer in the future. 914 N.E.2d 891, 899 (Mass. 2009). The court 
recognized subcellular injury as a present physical injury. Id. at 901. The court 
stated that “[w]e must adapt to the growing recognition that exposure to toxic 
substances and radiation may cause substantial injury which should be compensable 
even if the full effects are not immediately apparent.” Id.; see also Werlein v. United 
States, 746 F. Supp. 887, 901 (D. Minn. 1990), vacated in part on other grounds,
793 F. Supp. 898 (D. Minn. 1992) (denying the defendant’s motion for summary 
judgment because “[b]ased on the record before it, this Court cannot rule as a matter 
of law that plaintiffs’ alleged injuries are not ‘real’ simply because they are 
subcellular”).
288. Pizzirusso, supra note 281, at 198-204. 
289. Generally, plaintiffs are required to prove: (1) exposure greater than 
normal; (2) to a proven hazardous substance; (3) due to defendant’s negligence; (4) 
plaintiff has a significantly increased risk of contracting a serious latent disease as a 
proximate result of the exposure; (5) a medical monitoring procedure exists that 
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An early case that influenced the development of the doctrine 
involved potential brain injury. In Friends for All Children, Inc. v. 
Lockheed Aircraft Corp.,290 the court examined a claim brought on 
behalf of 150 Vietnamese orphans who survived a military transport 
plane crash.291 The plaintiffs sought injunctive relief to require the 
plane’s manufacturer to fund a medical surveillance program to 
determine whether depressurization of the plane’s cabin caused the 
children to suffer brain injury.292 The court agreed that the 
manufacturer should compensate the children for the monitoring 
costs, reasoning that such compensation was no different from an 
ordinary tort damage award: 
[E]ven in the absence of physical injury [the plaintiff] ought to be able to 
recover the cost for the various diagnostic examinations proximately 
caused by [the defendant’s] negligent action. . . . The cause of action . . . 
accords with commonly shared intuitions of normative justice which 
underlie the common law of tort. . . . [I]n this case, the crash exposed the 
plaintiffs to the risk of serious brain damage . . . [and] comprehensive 
diagnostic examinations are needed to determine whether and to what 
extent treatment may be necessary.293
Courts and commentators used the language in the case to 
suggest that it opened the door to a new claim of medical 
monitoring.294 The claim was more firmly established by the New 
Jersey Supreme Court in Ayers v. Township of Jackson.295 There, the 
New Jersey Supreme Court upheld a jury’s decision to award 
medical monitoring costs for plaintiffs who were exposed to toxic 
                                                                                                               
makes early detection of the disease possible; and (6) the monitoring regime is 
reasonably necessary according to accepted scientific principles. See Redland Soccer 
Club, Inc. v. Dep’t of Army, 696 A.2d 137, 145-46 (Pa. 1997). States generally 
require expert testimony to support the claim with proof that the monitoring is 
reasonable and necessary. They also allow traditional defenses to the claim, such as 
assumption of risk and contributory negligence. The relief ordered may vary: Some 
courts will order court-supervised programs; others will order defendants to pay 
plaintiffs certain sums of money; and others will require defendants to pay plaintiffs’ 
medical expenses directly. See generally Jonathan I. Handler et al., A Growing 
Number of States Recognize Medical Monitoring Claims, 25 BNA INSIGHTS 222 
(2010). 
290. 746 F.2d 816 (D.C. Cir. 1984). 
291. Id. at 819.  
292. Id. at 822. 
293. Id. at 825.  
294. D. Scott Aberson, Note, A Fifty-State Survey of Medical Monitoring 
and the Approach the Minnesota Supreme Court Should Take When Confronted with 
the Issue, 32 WM. MITCHELL L. REV. 1095, 1099 (2006). 
295. 525 A.2d 287, 312 (N.J. 1987). 
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pollutants from a landfill that had leached into residential drinking 
water: 
[W]e hold that the cost of medical surveillance is a compensable item of 
damages where the proofs demonstrate, through reliable expert testimony 
predicated upon the significance and extent of exposure to chemicals, the 
toxicity of the chemicals, the seriousness of the diseases for which 
individuals are at risk, the relative increase in the chance of onset of 
disease in those exposed, and the value of early diagnosis, that such 
surveillance to monitor the effect of exposure to toxic chemicals is 
reasonable and necessary.296
A number of courts followed suit, using the Ayers court’s 
factors to permit post-exposure, pre-symptom medical monitoring 
damages.297 The United States Supreme Court reached a different 
conclusion in a case arising under a federal statute. In Metro-North 
Commuter Railroad Co. v. Buckley,298 the Court construed the 
Federal Employers’ Liability Act (FELA) to require a showing of 
physical symptoms before medical monitoring costs can be 
awarded.299 The Court did not want to create “a new, full-blown, tort 
cause of action” for a variety of policy reasons, in particular to 
protect the interests of potential future plaintiffs not before the 
court.300
Although Buckley is not binding on the states, a number of 
states have followed the Supreme Court’s lead, requiring a showing 
of physical injury before allowing a medical monitoring claim or a 
claim for emotional distress for increased risk to go forward.301 For 
                                                     
296. Id.  
297. See, e.g., In re Paoli R.R. Yard PCB Litig., 35 F.3d 717, 787 (3d Cir. 
1994); Burns v. Jaquays Mining Corp., 752 P.2d 28, 33-34 (Ariz. Ct. App. 1987); 
Potter v. Firestone Tire & Rubber Co., 863 P.2d 795, 821-25 (Cal. 1993); Redland 
Soccer Club, Inc. v. Dep’t of Army, 696 A.2d 137, 144-45 (Pa. 1997); Hansen v. 
Mountain Fuel Supply Co., 858 P.2d 970, 979-81 (Utah 1993). In contrast, Nevada 
has held that medical monitoring claims could proceed even in the absence of 
physical injury. See Sadler v. PacifiCare of Nev., Inc., 340 P.3d 1264, 1264 (Nev. 
2014).  
298. Metro-N. Commuter R.R. Co. v. Buckley, 521 U.S. 424 (1997). 
299. Id. at 440 (interpreting FELA, 45 U.S.C. §§ 51-50 (1997)). 
300. Id. at 443. The Court found that mere exposure to a substance is 
insufficient, in light of concerns of a “‘flood’ of less important cases (potentially 
absorbing resources better left available to those more seriously harmed) and the 
systemic harms that can accompany ‘unlimited and unpredictable liability’ (for 
example, vast testing liability adversely affecting the allocation of scarce medical 
resources).” Id. at 442.
301. See, e.g., Genereux v. Raytheon Co., 754 F.3d 51, 56 (1st Cir. 2014) 
(denying claim for medical monitoring for beryllium-related diseases because 
plaintiffs did not demonstrate subcellular change). The court distinguished risk and 
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states that require a showing of physical injury, some (but not all) 
states allow plaintiffs to satisfy the requirement by demonstrating 
asymptomatic subcellular changes to indicate exposure and increased 
risk of future disease.302
Under either view—requiring physical symptoms or not—
development of biomarkers of effect, both of concussive injury in 
general and CTE in particular, may make a medical monitoring claim 
more viable in the youth sports area. Like the plaintiffs in Friends for 
All Children, claimants can show exposure by physical impact. For 
those states that require physical symptoms stemming from 
exposure, the plaintiff may be able to demonstrate through biomarker 
evidence that these repeated blows resulted in objectively 
measurable concussive or even (asymptomatic) subconcussive 
                                                                                                               
harm and found that plaintiffs’ expert “disclaimed any ability to state that any one 
plaintiff . . . had already suffered harm (that is, subcellular or other physiological 
change).” Id.; Paz v. Brush Engineered Materials, Inc., 949 So. 2d 1, 5-6 (Miss. 
2007) (rejecting claim “for mere exposure to a harmful substance without proof of 
current physical or emotional injury from that exposure”); Sinclair v. Merck & Co., 
948 A.2d 587, 595-96 (N.J. 2008) (rejecting claim in pharmaceutical products case); 
Lowe v. Philip Morris USA, Inc., 183 P.3d 181, 187 (Or. 2008) (rejecting claim in 
absence of current physical injury). A subsequent Supreme Court case, Norfolk & 
Western Railway Co. v. Ayers, suggested that workers suffering from asbestosis, a 
non-malignant respiratory disease that arises from exposure to asbestos, would be 
sufficient to satisfy the physical injury requirement for latent injury claims. 538 U.S. 
135, 148 (2003).  
302. In Donovan v. Philip Morris USA, Inc., the plaintiffs alleged that 
Marlboro cigarette smoke, with excessively high levels of carcinogen, caused 
physiological changes and lung tissue damage that led to significantly increased risk 
of lung cancer in the future. 914 N.E.2d 891, 895 (Mass. 2009). The Court 
recognized subcellular injury as a present physical injury. Id. at 898. The Court 
explained, “We must adapt to the growing recognition that exposure to toxic 
substances and radiation may cause substantial injury which should be compensable 
even if the full effects are not immediately apparent.” Id. at 901; see also Werlein v. 
United States, 746 F. Supp. 887, 901 (D. Minn. 1990), vacated in part on other 
grounds, 793 F. Supp. 898, 901 (D. Minn. 1992) (denying the defendant’s summary 
judgment because “[b]ased on the record before it, this Court cannot rule as a matter 
of law that plaintiffs’ alleged injuries are not ‘real’ simply because they are 
subcellular”). A federal district court, in approving the recent NFL settlement, 
refused to recognize a claim for subclinical injury compensation. In re Nat’l 
Football Players’ Concussion Injury Litig., 307 F.R.D. 351, 409 (E.D. Pa. 2015). 
Although objectors to the settlement argued that retired football players should 
receive compensation for CTE before death, the district court denied the claim. Id. at 
399. The court found that, even assuming a biomarker of abnormal tau protein 
during life will be available in the next decade, the presence of a marker alone does 
not indicate that the individual has or will develop symptoms of CTE. Id. at 402. 
(“The Settlement compensates symptoms that cause Retired Players to suffer, not 
the presence of abnormal tau protein (or any other irregular brain structure) alone.”).
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injuries. If biomarkers of CTE are developed, then that will 
strengthen the latent injury claims even more.  
From a broader perspective, development of biomarkers will 
challenge what we mean by a showing of physical symptoms of 
disease connected to the exposure in latent injury claims.303 Professor 
Jamie Grodsky has argued, for example, that courts generally need to 
rethink the concept of “physical injury” as advances in genetic 
science make it easier to detect the consequences of toxic exposure 
before the manifestation of clinical symptoms of disease.304 The same 
challenge will be presented here.  
Biomarker evidence will also be used to fulfill another 
element—demonstrating a significant increased risk of disease. 
Availability of this evidence could be a double-edged sword, 
however, making a latent injury claim even harder to prove if the 
biomarkers are not present in an exposed plaintiff. For example, in 
Sheridan v. NGK Metals Corp.,305 plaintiffs claimed that exposure to 
beryllium dust and particulates increased their risk of developing 
chronic beryllium disease (CBD) and asked the court to establish a 
fund to have beryllium manufacturers and suppliers pay for the costs 
of medical surveillance.306 The Third Circuit upheld the lower court’s 
dismissal of the claim, holding that the plaintiffs failed to provide 
medical tests demonstrating that they had immunological markers 
showing a predisposition to developing CBD after exposure to 
beryllium. Comparing the case to a prior case (Pohl),307 the court 
explained:  
Because the plaintiffs in Pohl were not beryllium sensitized and had not 
otherwise made a plausible showing that they faced a ‘significantly 
increased risk’ of developing CBD, the [Pohl court] held that these 
plaintiffs had failed to make a prima facie showing of their medical 
monitoring claim under [the increased risk test].308
The injury threshold for CTE—the severity and number of 
injuries that is required to trigger brain changes that lead to CTE—is 
still not known.309 Not everyone who has been subjected to repetitive 
concussive injury develops CTE; other risk factors, such as genetic 
                                                     
303. See Grodsky, supra note 276, at 1712-14; Marchant, Genetics and Toxic 
Torts, supra note 113, at 950.  
304. Grodsky, supra note 276, at 1712-14.  
305. 609 F.3d 239 (3d Cir. 2010). 
306. Id. at 247.  
307. Pohl v. NGK Metals Corp., 936 A.2d 43 (Pa. Super. Ct. 2007). 
308. Sheridan, 609 F.3d at 248.  
309. See Johnson, Partridge & Gilbert, supra note 212, at 16. 
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background, age, sex, or substance abuse, may come into play as 
causal factors.310 Like the court in Sheridan, a court may require a 
showing that the plaintiff has a detectable predisposition to develop a 
particular disease after exposure. We may reach agreement on 
general causation—that repeated blows to the head can lead to CTE. 
It may be still be difficult, however, to show specific causation—the 
specific, increased risk to the individual—without demonstrating that 
the individual has biomarkers to indicate individual susceptibility.311
Existing biomarkers for CTE may or may not address this individual 
increased risk; the detection of abnormal tau tangles in the living 
brain may not necessarily indicate the development in the future of 
CTE. Long-term longitudinal studies may be needed to demonstrate 
this higher risk among the “exposed” population. 
Relatedly, plaintiffs who seek damages for emotional harm will 
need to demonstrate that they have a genuine fear of developing the 
future disease, which is objectively reasonable.312 Although plaintiffs 
may be able to demonstrate the individual subjective fear through 
traditional proof, such as sleeplessness and other indications of 
anxiety, this may not be sufficient to meet the objective element of 
the claim. The objective criterion requires proof on the likely 
increased risk for an individual developing CTE.313 When biomarkers 
of CTE, in conjunction with epidemiological studies, enhance our 
knowledge of the increased risk, this may indicate the 
“reasonableness” of the fear of harm. In contrast, the absence of a 
biomarker may indicate that the fear is unreasonable and bar 
recovery for the emotional-harm claim.  
The paramount challenge is to determine whether a biomarker 
is sufficiently predictive to qualify for any type of latent injury 
claim. In other words, we need to separate valid from speculative 
claims, dividing those who are “injured” from those who are merely 
                                                     
310. Id.
311. See DOBBS, supra note 210, at 535-36 (explaining general and specific 
causation). 
312. See Andrew R. Klein, Fear of Disease and the Puzzle of Futures Cases 
in Tort, 35 U.C. DAVIS L. REV. 965, 974-79 (2012) (discussing cases). But see
RESTATEMENT (THIRD) OF TORTS: PHYSICAL & EMOTIONAL HARM § 46 cmt (h) 
(AM. LAW INST. 2012) (distinguishing “cancerphobia” claims from other emotional 
distress claims). 
313. See Potter v. Firestone Tire & Rubber Co., 863 P.2d 795, 811 (Cal. 
1993) (requiring a showing of significant increased risk of contracting future injury 
to support an emotional harm claim). 
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at some “risk.”314 As science can get us closer to a more accurate 
predictive measure, the recognition of these claims should be 
commensurate. This approach would comport with the policy 
reasons behind the claims—to detect disease at an early stage and to 
allow for medical intervention to reduce or eliminate the impact of 
the disease, ultimately reducing overall health care costs, as well as 
to serve social policy.  
Of course, the development of biomarkers to detect early signs 
of CTE does not address the effectiveness of early intervention. At 
this stage, medicine does not have a way to arrest the development of 
CTE, other than ceasing additional impacts. The lack of proven 
treatments challenges—at least partially—the objective behind 
awarding damages for post-exposure but pre-clinical symptom 
claims, since the plaintiff may not be able to demonstrate a need for 
special testing or medical intervention. Presumably, advances in 
discovering biomarkers will also spark development in subcellular 
interventions.  
Even with these reservations, development of biomarkers of 
effect should serve to address the jurisprudential and practical 
concerns of the courts in this area. They should help identify who is 
likely to develop certain diseases among those exposed to risk.315
This will serve the values of deterrence as well as the utilitarian 
concern of adequate resources.  
3. Causal Proof 
In proving the causal element of a tort claim, plaintiff bears the 
burden of showing that an injury can be caused by defendant’s 
negligence (general causation) as well as showing that the 
defendant’s negligence did cause plaintiff’s harm (specific 
causation).316 Biomarkers of effect can provide powerful evidence of 
both elements of causation. The lack of such biomarkers can be used 
by the defendant to argue against causation.  
                                                     
314. This was an area of significant dispute in the settlement between players 
and the NFL. See In re Nat’l Football Players’ Concussion Injury Litig., 307 F.R.D. 
351, 365-66, 396-423 (E.D. Pa. 2015).
315. While this Article does not address class action litigation per se, the 
advances in biomarker research should help to individualize claims rather than 
require remedies based on exposures and general averages.  
316. DOBBS, supra note 210, at 535-36 (2000). Sometimes we do not need 
to separate out these two questions, since it is obvious that the action can and did 
cause the injury, such as a broken limb stemming from a car accident.  
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Proving causation of injury is a major hurdle in bringing a 
lawsuit to recover for concussive injuries.317 The first issue is 
whether the plaintiff has actually incurred a concussion. Using self-
reported symptoms to show causation of concussive injury is 
naturally subject to attack as self-interested testimony.318 As an 
objective measure, biomarkers will help to demonstrate whether an 
actual concussive injury has occurred, leaving less room for 
challenge.319
Next, plaintiffs must prove their symptoms were caused by an 
activity associated with the defendant. In the simple case of a 
concussion that immediately results from a single impact, the nexus 
between exposure and effect will be straightforward. However, 
proving causation of long-term injuries like CTE presents more 
difficult challenges. Most concussions do not result in long-term 
effects.320 For those concussions that do result in cognitive and other 
effects, these results may take a long time to manifest, which makes 
proof of causation and injury even more challenging. Long latency 
periods open the door to problems of multiple causal factors. 
Moreover, the passage of time between the initial “exposure” and the 
manifestation of the full-blown disease may erode the plaintiff’s 
ability to prove the amount and length of exposure to concussive 
injury. Furthermore, we do not yet know precisely the amount of 
repetitive concussive injuries required to produce CTE or how long 
CTE takes to manifest. The latency period for CTE is likely to vary 
from individual to individual. This indeterminacy adds to causal 
problems.  
Development of biomarkers for CTE may address some of 
these challenges. It may turn out that CTE is a signature disease—
only stemming from repetitive head trauma—with a signature 
                                                     
317. Douglas K.W. Landau, Proving Damages in Child Concussion Cases,
TRIAL, Sept. 2014, at 40-41.  
318. Stockard R. Hickey III, Defending Questionable Mild Traumatic Brain 
Injury Claims, FOR DEF., June 2014, at 14, 17.  
319. See Rael T. Lange et al., Diffusion Tensor Imaging Findings and 
Postconcussion Symptom Reporting Six Weeks Following Mild Traumatic Brain 
Injury, 30 ARCHIVES CLINICAL NEUROPSYCHOLOGY 7, 7-8, 22 (2015) (finding that 
mere involvement in personal injury litigation, among other facts, tends to increase 
self-reported symptoms). 
320. Michael McCrea et al., Acute Effects and Recovery Time Following 
Concussion in Collegiate Football Players: The NCAA Concussion Study, 290 
JAMA 2556, 2556, 2560 (2003); Can Concussions Impact Memory or Intelligence?,
UPMC HEALTH BEAT (Dec. 4, 2014), http://share.upmc.com/ 2014/12/can-
concussions-impact-memory-intelligence. 
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abnormal pattern of the tau protein. Even more significant, the 
development of biomarkers of CTE may allow plaintiffs to bring suit 
during their lifetimes, without having to wait for a definitive autopsy. 
Challenges will continue to exist, however, even with that 
development. The paramount question is whether the biomarker, 
which will likely be probabilistic and not determinative, is 
sufficiently predictive of the full-blown disease to qualify as proof of 
causation. In other words, testing to determine the presence of a 
specific protein does not yet tell us how likely it is that an individual 
will develop cognitive disorders because of exposure to head trauma. 
This evidence may need to be supplemented by traditional, 
population-based epidemiological studies that estimate exposure and 
risk of disease.  
Defendants facing civil liability will use the absence of 
biomarkers to argue the lack of causal proof. This may create an 
even higher hurdle for plaintiffs in meeting their burden of proof. 
Further, as more biomarkers are identified, plaintiff’s burden on this 
element of their claim may only be increased.  
Defendants may also use biomarkers of effect to argue 
alternative causation.321 Plaintiffs claiming that they acquired CTE 
through the negligent behavior of defendants will need to 
demonstrate that their symptoms stem from defendants’ activities. 
Defendants will argue that the symptoms stem from other diseases, 
like Alzheimer’s, which the plaintiff may have acquired anyway. 
Given that 20% of the population may develop Alzheimer’s,322 the 
absence of a biomarker of effect in that individual patient may 
buttress the defendants’ arguments. Furthermore, a plaintiff may 
have been serially exposed to head trauma—in youth, college, and 
professional sports, for example—and therefore, linking the 
plaintiff’s condition to any particular defendant could be 
problematic.323 Advances in biomarkers research may not resolve the 
causal indeterminacy problem presented in this context. This may be 
                                                     
321. See, e.g., Fisher v. United States, 705 F. Supp. 2d 57, 67-68 (D. Mass. 
2010) (discussing whether a seizure disorder could have been caused from prior 
football concussions or from another cause).  
322. About Alzheimer’s Disease, ALZHEIMER’S FOUND. AM., http://www. 
alzfdn.org/AboutAlzheimers/statistics.html (last visited Feb. 13, 2016). 
323. See Julie M. Stamm et al., Age at First Exposure to Football Is 
Associated with Altered Corpus Callosum White Matter Microstructure in Former 
Professional Football Players, 32 J. NEUROTRAUMA 1768, 1768 (finding a greater 
risk of brain-development alterations for players who played tackle football between 
the ages of ten and twelve than those who started playing later). 
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further complicated when a plaintiff’s own negligent conduct, such 
as failure to report symptoms of a concussion, may be a competing 
potential cause of his harm, as discussed below.  
4. Defenses 
Affirmative defenses such as assumption of risk and 
contributory fault, which can limit the duty of schools, sports teams, 
and leagues to participants, will also be affected by the development 
and implementation of biomarkers.324 The assumption-of-risk defense 
focuses on a participant’s subjective, individual awareness of the risk 
and the voluntary nature of consent to encounter that known risk.325
                                                     
324. The classic defense of assumption of risk or informed consent in this 
context raises a host of questions about the validity of and power to consent, as well 
as absolving the sponsoring entity from liability. The underlying premise of the 
doctrine is that individuals have fully consented to incur a risk which they 
thoroughly comprehend. DOBBS, supra note 210, at 535-37. If the consent is valid, it 
will ordinarily relieve the defendant of the duty that may have otherwise existed. Id.
at 541-43. This means that the consent may overcome duties like the duty to screen, 
inform, accommodate, or exclude. For example, although the NCAA requires testing 
for SCT, the athlete can waive the right to receive the results of the testing. Sickle 
Cell Trait, NCAA, http://www.ncaa.org/health-and-safety/medical-conditions/ 
sickle-cell-trait (last visited Feb. 13, 2016). But there are public policy limits on 
consent. See DOBBS, supra note 210, at 542 (“Possibly . . . schools should not be 
allowed to condition a student’s participation rights on a general release of all 
liability for negligence.”). At the other extreme, courts generally view participation 
in interscholastic sports as a privilege rather than a legally protected right, so that a 
school can refuse to allow an athlete to play, even if the athlete or parent proffers a 
waiver. See, e.g., Farver v. Bd. of Educ., 40 F. Supp. 2d 323, 324 (D. Md. 1999) 
(noting the Due Process Clause does not protect a student’s interest in 
extracurricular activity participation, including sports); Peterson v. Indep. Sch. Dist., 
No. 811, 999 F. Supp. 665, 674 (D. Minn. 1998) (finding there is no protected 
interest in student’s extracurricular activities); Mancuso v. Mass. Interscholastic 
Athletic Ass’n, Inc., 900 N.E. 518, 527-28 (Mass. 2009) (finding no constitutionally 
protected right to participate in extracurricular athletics). Full comprehension of 
risks and voluntariness of consent raises a host of questions. For example, how well-
known are the risks and the extent of the risks? Would the athlete need to know the 
nature and extent of the eventual harm, such as CTE, or is it sufficient that the player 
be willing to undergo risks of some brain injury, like a mild, temporary concussion? 
As knowledge of the science of concussions changes, how will the duty to warn 
affect informed consent? What if the student athlete wants to sign the waiver, but the 
parents do not, or the parents are divorced and disagree about consent? These 
questions will increase with the development of biomarkers and the expanded 
understanding of concussions as a spectrum of injury. 
325. See RESTATEMENT (SECOND) OF TORTS § 496(C) (AM. LAW INST.
1965).  
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Defendants have traditionally been successful in asserting 
assumption of risk defenses in sports, including football.326
Availability of biomarkers may affect the assertion of an 
assumption-of-risk defense. This is because these scientific 
developments will affect the knowledge of the parties involved with 
regard to the prevention, diagnosis, and treatment of concussive 
injury.327 Use of biomarkers will change the diagnostic process and 
remove much of the ambiguity surrounding “medical clearance” to 
play.328 A player’s subjective knowledge of injury may become more 
readily provable with the development and availability of 
biomarkers. A player who goes on the field despite that knowledge 
may be deemed to have subjectively and deliberately assumed the 
concussion risk. Similarly, use of biomarkers may help clarify the 
validity of the player’s consent, since neither the player nor the 
evaluator will need to rely solely on the player’s processing of his 
own symptoms.329 With more precise information will come a more 
informed consent to play. 
At the same time, a significant question is whether the decision 
to participate can be truly autonomous, especially when the injuries 
themselves might impair the ability to consent in the future.330
Neurocognitive impairment may be delayed. This raises questions, in 
turn, about the extent to which participants understand the risks of 
acquired brain injury and the extent to which they can voluntarily 
                                                     
326. See, e.g., Heather MacGillivray, Where Is the Awareness in Concussion 
Awareness: Can Concussed Players Really Assume the Risk in a Concussed State?,
21 JEFFREY S. MOORAD SPORTS L.J. 529, 529 (2014) (stating the risk of concussion 
in football is generally known); Cailyn M. Reilly, Where Is Concussion Litigation 
Headed? The Impact of Riddell, Inc. v. Schutt Sports, Inc., on Brain Injury Law, 20 
JEFFREY S. MOORAD SPORTS L.J. 517, 517 (2013) (noting that concussions are “the 
reality of contact sports”).
327. See MacGillivray, supra note 326, at 551 (noting that the “devastating 
long-term effects of concussions have become glaringly clear due to an explosion of 
scientific research and public attention” to lawsuits against sports leagues).  
328. See cf. Joseph M. Hanna & Daniel Kain, NFL’s Shaky Concussion 
Policy Exposes the League to Potential Liability Headaches, 21 N.Y. ST. B. ASS’N
ENT. ARTS SPORTS L.J., Fall/Winter 2010, at 33, 36 (2010) (explaining that the 
NFL could argue that plaintiffs were contributorily negligent “by (1) failing to report 
their concussive conditions to team doctors, and (2) returning to play before their 
concussion symptoms completely disappeared”).
329. See Alex Taylor, Neuropsychological Evaluation and Management of 
Sport-Related Concussion, 24 NEUROLOGY 717, 717 (2012) (citing evidence that 
suggests that “up to 90% of sports-related concussions may go undetected or 
unreported”).
330. See generally MacGillivray, supra note 326 (arguing that an athlete in a 
concussed state cannot validly assume the risk of continued play).  
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assume those risks. This issue is also plagued by questions of 
coercion and competing interests.331 Even if a player can knowingly 
and voluntarily assume the risk of a concussion, this does not speak 
to the awareness and knowledge of the heightened risk of a second 
concussive injury or the long-term effects of repetitive concussions 
and cognitive decline. Nor does it speak to the risk of subconcussive 
impacts that may have similar effects but do not present with
observable concussive symptoms.332 In that case, the player is not 
aware of the risks presented, particularly of playing in a concussed 
state. These problems throw the player’s capacity to consent into 
question.  
Furthermore, given the quickly changing developments of 
science in this area, it is unclear whether parents and students can 
ever validly consent to exposure to such an uncertain and changing 
risk. Would consent that is knowingly and voluntarily given still be 
binding when new risks come to light?  
Similarly, if individuals are found to be susceptible to 
concussion, whether by biomarkers or because of previous injury, 
then this finding will pose the question whether the individuals (or 
their parents) can lawfully assume the risk of injury. This may 
depend on the degree of susceptibility the test indicates. Certain 
levels of susceptibility may always require exclusion from 
assumption of risk and participation. These questions are explored 
below.  
B. Legal Implications of Biomarkers of Susceptibility 
Development of biomarkers of susceptibility will help 
distinguish individuals more susceptible to concussive injury than 
the general population. Biomarkers of susceptibility are subject to 
the same constraints as biomarkers of effect: They are likely to be 
probabilistic rather than determinative, so there are unlikely to be 
bright-line demarcations between affected and non-affected, and 
susceptible and non-susceptible, individuals. A further complication 
is that susceptibility may be affected by various circumstances such 
                                                     
331. See Benitez v. N.Y. City Bd. of Educ., 541 N.E.2d 29, 33 (N.Y. 1989) 
(“Though the risk is foreseen, an assurance of safety generally implicit in the 
supervisor’s direction supplants the plaintiff’s assumption of the risk by requiring 
action despite prudent cautionary concerns.”).
332. See McAllister et al., supra note 78, at 66.  
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as the number and type of concussive injuries suffered, gender, age, 
or even ethnic background, or a combination of these factors.333
Notwithstanding these variables, recent findings suggest that 
biomarkers of susceptibility are likely to be identified in the near 
future, as discussed above. In particular, the presence of the genetic 
variant APO ϵ4 may be an important biomarker for susceptibility to 
concussions.334 In addition, concussion susceptibility is present in 
those who have previously suffered brain injuries.335 With the 
growing capability to determine concussion susceptibility based on 
biomarkers, we can anticipate a commensurate impact on the legal 
landscape.  
1. Duty to Screen for, Warn, and Potentially Exclude from 
Activities Individuals with Increased Concussion Risk 
Whether a duty to screen players for susceptibility to 
concussive injury exists involves implementation of the classic cost–
benefit analysis in tort law: The likelihood of injury must be high 
enough and the risk severe enough that that the “costs” of the 
potential injury outweigh the cost of screening.336
While it is not yet established whether the ϵ4 allele actually 
increases susceptibility to TBI and CTE,337 this Article assumes that 
it does to demonstrate the complexity of this analysis. The frequency 
of the ϵ4 allele is approximately 14% in the general population.338
                                                     
333. See Frederica P. Perera, Environment and Cancer: Who Are 
Susceptible?, 278 SCIENCE 1068, 1070-71 (1997) (discussing age, gender, and 
ethnicity as influencing susceptibility of cancer). 
334. See supra Subsection I.C.3.  
335. See supra note 80 and accompanying text.  
336. See United States v. Carroll Towing Co., 159 F.2d 169, 173 (2d Cir. 
1947) (discussing the “Learned Hand formula” of duty; balancing the magnitude of 
the loss if an accident occurs, the probability of the accident’s occurring, and the 
burden of taking precautions that would avoid it). 
337. See supra Subsection I.C.3.  
338. Alzgene - Meta-Analysis of All Published Ad Association Studies (Case-
Control Only) APOE_E2/3/4, ALZFORUM, http://www.alzgene.org/meta.asp? 
geneID=83 (last updated Jan. 29, 2010); Nader Ghebranious et al., Detection of 
ApoE E2, E3 and E4 Alleles Using MALDI-TOF Mass Spectrometry and the 
Homogeneous Mass-Extend Technology, 33 NUCLEIC ACIDS RES. e149, e149 
(2005) [hereinafter Alzgene Meta Analysis]. The allele frequency is the percentage 
of a particular allele among all chromosomes. Allele Frequency, SCIENCEDAILY,
http://www.sciencedaily.com/terms/allele_frequency.htm (last visited Feb. 13, 
2016). In this case, 14% of chromosomes in the general population contain the APO 
ϵ4 allele, as opposed to carrying the ϵ2 or ϵ3. Alzgene Meta Analysis, supra, at e149.  
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The homozygous ϵ4 genotype is found in approximately 2% of the 
population.339 These data show that the ϵ4 allele is relatively rare and 
the ϵ4 genotype is only found among a small percentage of the 
population, suggesting a lower percentage of the population is at 
risk. Severity of injury must be taken into account as well, however, 
which could be substantial in the concussive injury area.  
An analogous precedent of this analysis is the obligation of the 
NCAA football teams, pursuant to a settlement agreement in 
litigation brought by the family of a deceased college football player, 
to genetically screen their players for sickle cell trait (SCT).340
Carriers of SCT may be at an increased risk for serious harm from 
strenuous activity.341 SCT affects approximately 1.3% of the 
population and 8.3% of African Americans in the United States.342 As 
34% of college football players are African Americans, it could then 
be estimated that approximately 3% of college football players have 
SCT.343 While this is a small percentage of the overall population and 
also football players, the risk is significant enough that the NCAA 
has adopted program-wide screening for SCT for all contact sports.344
Researchers have estimated that one death would be prevented 
within four years of implementing the program and that seven would 
be saved in ten years,345 with the cost of implementation estimated to 
be between $1,441,810 and $2,883,620 (based on estimating the cost 
of testing for SCT to be between $10 and $20) over the course of 
                                                     
339. Alzgene Meta Analysis, supra note 338, at e149. As previously noted in 
the Article, the ϵ4 genotype has been found to correlate to an even higher risk of TBI 
and CTE than a single copy of the ϵ4 allele. See supra notes 193-207 and 
accompanying text.  
340. See Deborah Levenson, College Athletes Should Get Sickle Cell Trait 
Tests, NCAA Advises, 152A AM. J. MED. GENETICS C1, fm ix (2010).  
341. See Beth A. Tarini, Margaret Alison Brooks & David G. Bundy, A
Policy Impact Analysis of the Mandatory NCAA Sickle Cell Trait Screening 
Program, 47 HEALTH SERVS. RES. 446, 454-55 (2012) (explaining that “[t]he 
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342. See Jonathan C. Goldsmith et al., Framing the Research Agenda for 
Sickle Cell Trait: Building on the Current Understanding of Clinical Events and 
Their Potential Implications, 87 AM. J. HEMATOLOGY 340, 340 (2012). 
343. Id. at 341. 
344. The agreement to screen was part of a settlement agreement and not 
actually found as a duty to screen as a matter of law. See In re NCAA Student-
Athlete Concussion Injury Litig., No. 13 C9116, 2014 U.S. Dist. LEXIS 174334, at 
*13-14 (N.D. Ill. Dec. 17, 2014); In re Nat’l Hockey League Players’ Concussion 
Injury Litig., No. 14-2551 (SRN), 2015 BL 82307, at *8 (D. Minn. Mar. 25, 2015).  
345. Tarini, Brooks & Bundy, supra note 341, at 453. 
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four years.346 This is in comparison to the cost of determining one’s
APOE genotype, which is available commercially as an Alzheimer’s
susceptibility test for $150 per test.347 While this cost could be 
lowered by large-scale purchasing, it may still be significantly higher 
than the cost of SCT screening.  
The duty to screen may vary depending on the sport involved, 
since concussion injury is more common in certain high-risk sports 
than others.348 Furthermore, screening may require more than testing 
for the presence of biomarkers of susceptibility, since susceptibility 
to concussive injury also increases with further head injuries.349
Screening for both medical history and biomarkers could more 
effectively narrow the list of players where action may be taken.350
Even assuming the development of biomarkers of susceptibility 
to concussive injury will engender a duty on school and sports 
organizations to screen athletes for susceptibility, questions remain 
about when to screen and what to do with this information. At one 
extreme, conducting screening may implicate a duty to exclude from 
play those individuals with susceptibility biomarkers. Short of 
exclusion, the activity sponsors may have a duty to warn those 
individuals of increased risk, monitor them more closely throughout 
the season, provide accommodations, and implement additional 
preventative measures to avoid concussion.351 These measures also 
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concussive injury include transportation, material moving, farming, fishing, forestry, 
and installation and repair occupations. See Svetla Slavova & Terry L. Bunn, Work-
Related Concussive Surveillance, 58 AM. J. INDUS. MED. 40, 41 (2015).  
351. The SCT provides a relevant precedent here too. The University of 
California at Berkeley football team offered SCT screening to its players, and player 
Ted Agu tested positive for the sickle cell trait. Nanette Asimov, Cal Football 
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depend on whether effective intervention measures are available and 
cost-effective.  
Another approach to susceptibility, and one commonly 
followed, is universal warnings and intervention, rather than 
universal screening and exclusion or accommodation. In other 
words, whatever warnings and accommodations are administered to 
reduce the likelihood of concussion during play (such as changing 
rules of play or requiring certain equipment) could be applied across 
the board to all players.352 In general, information on individual 
susceptibility will allow policy makers, as well as schools and other 
sports sponsors, to make concussive risk management decisions 
based on the probability of injury. 
2. Balancing the Duty to Screen and Warn Against Privacy 
Interests 
Screening for biomarkers of susceptibility will raise 
confidentiality and privacy concerns regarding a patient’s health 
information similar to those raised with the development of new 
technologies353 and medical tests, such as functional magnetic 
resonance imaging (fMRI) or genetic testing.354 The entity 
performing or ordering the screening for susceptibility will likely be 
held to a duty to warn the susceptible individual of an increased risk, 
and this may include disclosure to third parties, such as the 
                                                                                                               
Player Ted Agu’s Family Files Suit against UC, SFGATE (Aug. 6, 2014), 
http://www.sfgate.com/collegesports/article/Family-sues-UC-over-Cal-football-
player-s-death-5670060.php. During an intense practice session, Agu died from his 
sickle cell condition, and his family has sued the team for its failure to take 
appropriate action to protect the susceptible player. Id.
352. See Tarini, Brooks & Bundy, supra note 341, at 457-58 (concluding that 
universal SCT screening will identify a substantial number of sickle cell carriers). It 
is unclear whether screening is a necessary step to prevent exercise-related sudden 
death in student–athletes, and successful intervention measures are needed as well. 
Id.
353. The development of electronic recordkeeping and the Internet urged the 
federal government to adopt privacy regulations for health care providers in the 
Health Insurance Portability and Accountability Act (HIPAA). Health Insurance 
Portability and Accountability Act of 1996, Pub. L. No. 104-191, § 264, 110 Stat. 
1936, 2033; BARRY R. FURROW ET AL., HEALTH LAW: CASES, MATERIALS, AND 
PROBLEMS 104 (7th ed. 2013).  
354. See Stacey A. Tovino, Functional Neuroimaging Information: A Case 
for Neuro Exceptionalism?, 34 FLA. ST. U. L. REV. 415, 416 (2007).
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individual’s parents, coach, or employer.355 Releasing that 
information to others may conflict with the privacy interests of the 
susceptible individual in his medical information.356 At the same 
time, the results may have important implications for family 
members and others, and the issue arises whether those individuals 
have a right to that information as well. 
One important question is whether this information requires 
special or heightened privacy protections.357 This argument has been 
made regarding neuroimaging data and genetic testing in general.358
Like genetic testing, biomarkers of susceptibility will be newer and 
more complex than other medical tests and therefore will require 
careful consideration of privacy concerns associated with it. A
significant issue is whether this information is likely to carry a 
stigma, so that other policy reasons may dictate that it is important to 
control access to this health information.359
A number of third parties, like parents, employers, coaches, 
and insurers, will likely have a countervailing interest in obtaining 
the results of susceptibility testing. Generally, the Department of 
Health and Human Services (HHS) regulates information privacy 
through its Privacy Rule,360 but this only applies to “covered 
                                                     
355. See Stanley v. McCarver, 92 P.3d 849, 856 (Ariz. 2004) (holding that a 
doctor performing a screening test owed a duty of care to the patient even in the 
absence of a doctor–patient relationship because he was in a unique position to 
prevent future harm).  
356. See Michael K. McChrystal, No Hiding the Ball: Medical Privacy and 
Pro Sports, 25 MARQ. SPORTS L. REV. 163, 164 (2014).  
357. For example, HIV and AIDS test results have been treated with 
“exceptionalism” with regard to confidentiality and privacy. See, e.g., 35 PA. STAT.
AND CONS. STAT. ANN. § 7607(a) (West 2015) (making it unlawful for persons in 
control of HIV-related information to disclose or be compelled to disclose such 
information except in limited circumstances); Joyce J. Shin, Comment, Closing the 
Gap: Protecting Predictive Neuroscience Information from Health Insurance 
Discrimination, 64 EMORY L.J. 1433, 1435-36 (2015). Other health-related records 
receive special protection as well. See, e.g., 42 U.S.C. § 290dd-2(a) (2012) 
(specifying that records maintained in relation to substance abuse research, 
rehabilitation, or programs should remain confidential); 50 PA. STAT. AND CONS.
STAT. ANN. § 7111 (discussing privacy of mental health records). 
358. Tovino, supra note 354, at 416.
359. In reaction to the stigma attached to seeking help for substance abuse 
issues, for example, Congress enacted confidentiality regulations relating 
specifically to substance abuse patient records. 42 U.S.C. § 290dd-2(a); Emily 
Shrift, Subpoenas of Substance Abuse Patients Records, 39 MD. B.J. 49, 49 (2006).
360. 45 C.F.R. § 164.500 (West 2015).  
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entities,” such as physicians, hospitals, and health insurers.361 This 
leaves employers, leagues, courts, educational institutions, and others 
without many regulations and with strong potential interests in 
obtaining private medical information.362 The Genetic Information 
Nondiscrimination Act (GINA) prohibits employers and health 
insurers from accessing or utilizing genetic information,363 but it does 
not apply to other entities, such as life and disability insurers and 
schools, and does not apply to non-genetic information, such as brain 
scans.364
The use of concussion biomarkers in litigation could present 
some significant privacy concerns. In some cases, plaintiffs may seek 
to use their own biomarker data to make their case, but in other 
cases, the defendant may seek to discover sensitive biomarker data 
from the plaintiff. If the plaintiff objects, a judge must decide 
whether the defendant can gain access to the biomarker data under 
Rule 35.365 Because the plaintiff has put his or her health at issue, and 
given that plaintiffs may use the biomarker data themselves if the 
results favored their arguments, the court will likely allow the 
defendants to discover the plaintiffs’ biomarker data if there has been 
a basic showing of likely relevance.366
This compelled disclosure of biomarker status could have 
adverse consequences for the plaintiff. For example, APOE status 
not only discloses concussion risk, but also indicates risk of 
                                                     
361. 45 C.F.R. §§ 162.1101-1802, 164.104(a) (West 2015); see also Tovino, 
supra note 354, at 448. 
362. Tovino, supra note 354, at 449. The Privacy Rule also contains many 
exceptions allowing health care providers to use or disclose health information for 
law enforcement purposes, adjudicative proceedings, disease prevention and control, 
and even to prevent serious threats to the health and safety of the public or an 
individual person. 45 C.F.R. § 164.512 (West 2015). 
363. Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-
233, 122 Stat. 881, 884, 907 (2008); see also Daniel Schlein, New Frontiers for 
Genetic Privacy Law: The Genetic Information Nondiscrimination Act of 2008, 19 
GEO. MASON U. CIV. RTS. L.J. 311, 313 (2009). 
364. Some states have adopted their own privacy laws that go beyond the 
federal protections. See generally Tovino, supra note 354, at 457. For example, 
Arizona and California prohibit life and disability insurers from requesting genetic 
information from their clients. ARIZ. REV. STAT. § 20-448.02 (2015); CAL. INS. CODE
§ 10143(a) (West 2015).  
365. FED. R. CIV. P. 35 (authorizing courts to order physical and mental 
examination of party where that condition is in controversy).  
366. See Favale v. Roman Catholic Diocese of Bridgeport, 235 F.R.D. 553, 
555, 558 (D. Conn. 2006) (compelling examination when condition of party is in 
controversy and there is good cause for ordering an examination). 
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developing Alzheimer’s disease, something plaintiffs may not want 
to know about themselves and almost certainly would not want 
others to know.367 A college-level player hoping to be drafted may 
not want professional teams to learn that he has a susceptibility to 
concussions, as it may diminish his chances of being drafted.368
These privacy and disclosure issues are likely to create delicate 
situations for litigants, attorneys and judges.  
3. Comparative Fault Implications 
Susceptibility information will raise unique comparative fault 
questions. Typically, once liability is determined, damages in a tort 
lawsuit are based on restoring plaintiffs back to their prior position 
before the defendant breached his or her duty of due care to them.369
This rule applies to harms that are foreseeable,370 but in applying the 
foreseeability test, courts distinguish between the nature of a harm 
and its extent.371 Under the eggshell skull common law rule, courts 
hold that negligent actors take plaintiffs as they find them, even if the 
extent of injury is not foreseeable.372 Under that rule, the award of 
damages does not take into account whether the plaintiff is more 
susceptible to injury, even if the defendant had no reason to know of 
the plaintiff’s susceptibility.373
Even under this doctrine, however, the question remains 
whether a susceptible individual has the same right to recovery as a 
non-susceptible individual, or whether the injured party’s 
compensation should be reduced based on comparative fault or 
assumption of risk.374 In any event, measuring harm from concussive 
                                                     
367. Baugh et al., supra note 91, at 249.  
368. A professional sports team likely has an employer–employee 
relationship with its players, and so it could not require genetic testing of players 
under GINA. However, such information could be publicly released if disclosed 
during a court case or through testing by a college team, which likely is not 
considered an employer under GINA. While a protective order may be available to 
help protect the information disclosed in judicial proceedings, there will remain 
some risk of disclosure.  
369. See generally DOBBS, supra note 210, at 1047-53. 
370. Id. at 464-66. 
371. Id. at 464.  
372. Id. at 464-65. 
373. Id.
374. See, e.g., Marchant, Genetic Susceptibility, supra note 278, at 79, 88
(discussing the “thin skull” doctrine and susceptibility versus non-susceptibility in 
the context of toxic injury litigation as well as the possibility of an assumption of 
risk defense). 
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injury is difficult when the long-term consequences of concussion 
remain uncertain and yet can be so severe.  
Alternatively, a defendant may potentially assert the 
idiosyncratic response defense when an individual’s susceptibility to 
concussion is rare and unpredictable.375 The defense would be that 
the defendant cannot be held liable for an injury resulting from the 
plaintiff’s unusual susceptibility that a substantial portion of the 
population does not share.376 This defense has been applied in 
products liability actions.377 Defendants in toxic tort litigation have 
                                                     
375. See Marchant, Genetics and Toxic Torts, supra note 113, at 960-61
(describing defense in products liability cases). 
376. There are two early cases recognizing the defense. Griggs v. Comb, 
Inc., 456 So. 2d 790, 790-93 (Ala. 1984) (noting that the manufacturer “could not 
have known ‘by the application of reasonable, developed human skill and 
foresight’” that its product could cause the type of injury suffered by the plaintiff; 
the product was not defective when the plaintiff suffered an allergic reaction to 
benzocaine, the active ingredient in a topical analgesic); Bennett v. Pilot Prods. Co., 
235 P.2d 525, 527 (Utah 1951) (dismissing plaintiff’s action against beautician for 
applying a hair cold wave solution containing ammonium thioglycolate, which 
caused blistering and inflammation, reasoning that the court “cannot require the 
merchant to assume the role of absolute insurer against physiological idiosyncrasy”). 
377. See Mather v. L’Oreal USA, Inc. 695 S.E.2d 693, 693-95 (Ga. Ct. App. 
2010) (addressing a self-tanning lotion that caused pus-filled abscesses; noting that 
L’Oreal did not know that the product could cause such a reaction since its active 
ingredient, hydroxyacentone, was commonly used and accepted in dermatology as 
safe, and the manufacturer did not receive similar complaints during testing; 
summary judgment for manufacturer affirmed); see generally DAVID G. OWEN,
PRODUCTS LIABILITY LAW § 9.4 (2015); THOMSON REUTERS, AMERICAN LAW OF 
PRODUCTS LIABILITY § 32:52 (3d ed. 2015). 
  The idiosyncratic plaintiff defense originates in the Restatement 
(Second) of Torts, which states that a manufacturer has duty to warn of an allergic 
reaction to an ingredient where a “substantial number of the population are allergic” 
to the ingredient, and “the ingredient is one whose danger is not generally known, or 
if known is one which the consumer would reasonably not expect to find in the 
product.” See RESTATEMENT (SECOND) OF TORTS § 402A cmt. j (AM. L. INST. 
1977). The Restatement (Third) of Torts maintains the defense. It recognizes that 
“virtually any tangible product can contain an ingredient to which some persons may 
be allergic,” and thus, 
The general rule in cases involving allergic reactions is that a warning is 
required when the harm-causing ingredient is one to which a substantial 
number of persons are allergic. The degree of substantiality is not 
precisely quantifiable. Clearly the plaintiff in most cases must show that 
the allergic predisposition is not unique to the plaintiff. In determining 
whether the plaintiff has carried the burden in this regard, however, the 
court may properly consider the severity of the plaintiff’s harm. The more 
severe the harm, the more justified is a conclusion that the number of 
persons at risk need not be large to be considered “substantial” so as to 
require a warning. 
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argued successfully that they are not liable for harm from products 
that affect only genetically hyper-susceptible individuals.378 The 
difficulty in applying this defense is determining what responses are 
considered idiosyncratic and the applicable percentage cutoff.379
CONCLUSION
This is a transformative moment in society with regard to 
concussive injury. We are confronted with a public health crisis: 
Substantial risks of concussive injury already inhere in a variety of 
settings, ranging from sports injury, transportation accidents, military 
combat service, workplace injuries, falls, and domestic relations. The 
lack of objective tests for diagnosis, prognosis, and tracking of 
concussions, as well as the inability to measure individual 
susceptibility and response to concussions, is impeding effective 
policies for preventing and allocating responsibility for this 
concussion crisis. Yet the explosion of research to meet this public 
health crisis is leading to the identification of biomarkers that tell us 
who is more likely than not to be susceptible to harm and the extent 
of harm they may have already suffered. These developments have 
dramatic implications for the distribution of loss in terms of fault 
allocation, duty, and causation.  
Arriving at this inflection point demands that we reexamine 
how we apply basic tort doctrine to concussive injury cases and 
                                                                                                               
RESTATEMENT (THIRD) OF TORTS § 2 cmt. k (AM. L. INST. 2012).  
378. See Marchant, Genetics and Toxic Torts, supra note 113, at 961 (The 
“defense represents a policy judgment that a non-negligent manufacturer should not 
be held liable for producing a product that is beneficial and harmless to most 
persons, even if it may injure a small number of unusually susceptible individuals.”). 
See generally Marchant, Genetic Susceptibility, supra note 278, at 80-84.
379. Although it is beyond the scope of this Article, availability of this 
defense will have implications for products manufacturers of equipment in sports, 
such as helmet manufacturers. Manufacturers are held to a duty of producing a non-
defective product, which includes a duty to adequately test their products, as well as 
to warn of the limitations of the safety of the product. See generally RESTATEMENT 
(THIRD) OF PRODUCTS LIABILITY § 2 (1998) (describing three types of product 
defects). Manufacturers may also have a duty to test their products on individuals 
with different genetic susceptibilities. Manufacturers may be charged with providing 
a warning to an identifiable subgroup of susceptible individuals, especially if the 
individuals constitute a significant proportion of the product users. See Marchant, 
Genetic Susceptibility, supra note 278, at 79, 88 (discussing the “thin skull” doctrine 
and susceptibility versus non-susceptibility in the context of toxic injury litigation as 
well as the possibility of an assumption of risk defense). This would assume that the 
susceptible individuals have access to information that would identify their 
susceptibility. 
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make broad social policy decisions as well. Recall the examples in 
the Introduction. We need to reexamine whether athletes like Curtis 
Parker should reasonably expect his coach to be able to determine 
accurately whether he suffers from concussive injury. We also need 
to reconsider the implications of long-term damage. Should an 
athlete like Chris Benoit be entitled to a latent injury claim, such as 
medical monitoring, to address his increased risk of CTE? Could 
either Curtis Parker or Chris Benoit have made an informed choice to 
confront the risks of concussive injury in sport? And do players like 
Chris Borland have an obligation to be tested for susceptibility to 
concussive injury? In general, we need to confront whether the 
availability of biomarkers of effect and susceptibility should limit the 
players’ recovery in tort, or whether the primary responsibility for 
this population should be placed on the gatekeepers of the athletic 
field, such as athletic trainers, coaches, and schools. 
The biggest challenge in this area has always been one of 
imperfect scientific information, but we are on the cusp of making 
the unobservable observable.380 Scientific advances likely will bring 
further recognition of diseased states of concussive brain injury, 
which will dramatically alter what we mean by injury, risk, as well 
as causation in tort suits involving concussive injury. These elements 
may lose their sharp definitions as we are able to trace back earlier 
into what we think of as a diseased state. Proof of biomarkers of 
effect should shed light on causal issues in tort lawsuits, as well as 
duties, and may help to substantiate latent injury claims through the 
ability to examine long-term effects and injuries. Development of 
these biomarkers will shift legal responsibilities in the diagnosis and 
management of youth sports-related mTBIs to those most directly 
involved in the player’s participation, including trainers, schools, 
parents, and the players themselves. 
Biomarkers of susceptibility will identify a vulnerable 
population. This development will modify responsibilities in the duty 
to mitigate risks, the duty to monitor players in the short term as well 
as the long term, the duty to exclude or provide accommodations, the 
duty to inform, as well as the ability of players to consent to risks of 
head trauma. Practical concerns will also influence these 
responsibilities through application of the classic cost–benefit 
                                                     
380. See cf. Daniel A. Farber, Toxic Causation, 71 MINN. L. REV. 1219, 
1247 (1987) (“The only real difference between the automobile case and the toxics 
case is that better information is available about the events in the automobile case 
whereas the relevant biological events in the toxics case are unobservable.”).
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analysis that permeates tort law and public policy decisions. As the 
availability of biomarkers increase and their costs decrease, their use 
will become standard in concussive injury management. At the same 
time, increasing reliance on biomarkers will raise concerns relating 
to privacy and confidentiality.  
Ultimately, development of biomarkers should lead to a more 
accurate and just result in litigation surrounding concussive injury. 
At the same time, courts will be challenged to deal with the data 
presented in appropriate ways, since the data will be presented in 
ranges, and will likely not be determinative but rather probabilistic. 
Furthermore, these data may be complicated by other factors, such as 
gender, ethnicity, and age. Moreover, because use of this data may 
be unduly persuasive, courts will need to evaluate the information 
presented carefully in their role as gatekeepers of admissibility of 
scientific evidence. Finally, concussion biomarkers are likely to raise 
difficult privacy issues, which courts will need to address on a case-
by-case approach given the lack of applicability of most federal
medical privacy laws to the litigation context.  
Identification of biomarkers will also have an impact on the 
normative questions generated by activities that involve the risk of 
repetitive head trauma. Safety is a relative term. As we increase our 
understanding of the risks involved, society will confront on a more 
informed basis what risks are acceptable and for whom. 
Development of biomarkers may confirm that the risk of mTBIs or 
the associated risks of CTE changes depending on the age or gender 
of the individual or other factors. This will make us confront 
questions as fundamental as whether parents, coaches, schools, and 
others owe a duty to restrict children from the playing field. 

